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Abstract 
Prostate cancer (CaP) remains the most commonly diagnosed cancer and second leading cause of 
cancer mortality among men in several ethnic groups in the United States. Lower CaP incidence 
among Asian men has been attributed to increased intake of soy derived phytoestrogens (SDPs); 
however, its association has not been extensively explored in U.S. men. The purpose of this 
study was to determine the effect size of serum prostate specific antigen (sPSA) and serum 
estradiol (sE2) following dietary SDP intervention. The study was based on an original 
conceptual model that aims to avert early prostate tissue damage through identification of critical 
prevention endpoints. Research questions examined the correlation between dietary SDPs and 
sPSA and sE2 levels. This quantitative meta-analysis study used data abstracted from 8 
randomized controlled trials yielding 530 participants ages 50-85. Outcome specific meta-
analysis using the random effect model adjusted for heterogeneity and determined cumulative 
effect size that favored intervention. Odds ratios established a positive correlation between intake 
of dietary SDP and detection of serum SDP (sSDP) among treated groups. Positive correlations 
between both dietary and sSDP with sE2 levels, and inverse correlations between both dietary 
and sSDP with sPSA levels, were indicated among treated compared to placebo groups. Hedges’ 
g, correlation, and standardized mean difference statistics confirmed analyses. Implications for 
positive social change include developing professional dietary standards to use SDPs for CaP 
chemoprevention among U.S. and other men, as well as a medical option for treatment of CaP. 
Further research exploring mechanisms of SDP action on hormones may be beneficial to men at 
risk for CaP and individuals at risk for other cancers linked to changes in hormonal levels. 
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Chapter 1: Introduction to the Study 
Background of the Study 
Cancer is now the leading cause of mortality worldwide, with more than 7.6 
million cases (World Health Organization [WHO], 2012). Prostate cancer (CaP) among 
men in Western countries (Guy et al., 2008; Hill & Doyon, 2006; Jemal et al., 2007) is 
significantly higher in incidence rate than the rate observed among men living in Asian 
countries (Adlercreutz, Yamada, Wahala, & Watanabe, 1999; Marks et al., 2004; Miller, 
1988; Parkin, Pisani, & Ferlay, 1999). The observed lower incidence rate of CaP has been 
associated with higher intake of soy derived phytoestrogens (SDPs) in Asian countries 
(Adlercreutz et al., 1999). Longer life expectancy and improved screening methods are 
likely to increase the number of CaP cases within the global population (White et al., 
2004; White et al., 2010), and as many as 10%-15% of adult men could be affected 
(Bosland, 2000; Qin, Wang, Kaneko, Hoshi, & Sato, 2003; Singh, Matanhelia, & Martin, 
2008). Environmental causes have been implicated with mortality, while ethnic 
differences and consumption of soy as a dietary staple have been credited for some lower 
observed disease incidence (Adams, Chen, Newton, Potter, & Lampe, 2004; Hsing & 
Devesa, 2001).  
CaP is the most common noncutaneous cancer among males (Jemal et al., 2007; 
Sharma et al., 2009). The need for available chemoprevention and other therapies has 
generated tremendous interest within public health and medical communities (National 
Cancer Institute [NCI], 2012). While recent reports indicate a decline in some cancers, 
the incidence of CaP remains greater than 10% (American Cancer Society [ACS], 2012). 
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CaP is also the second leading cause of cancer mortality among men in the USA (ACS, 
2012; Centers for Disease Control and Prevention [CDC], 2012). The ACS estimated that 
in the year 2012, there were approximately 241,740 new cases and 28,170 deaths from 
CaP (ACS, 2012). Estimates of new cases for the year 2013 were slightly lower (238,590 
new cases) with an expected mortality of 29,720 (NCI, 2013). At diagnosis, CaP 
disproportionately affects African American (AA) men in both incidence and mortality 
compared to Whites (ACS, 2012; CDC, 2012). Age is not alterable and is an integral 
factor in the etiology of the disease (ACS, 2012; CDC, 2012). According to the CDC 
(2012), AAs are 1.86 times more likely to develop CaP before the age of 65 
(103.1/100,000), compared to European Americans (55.3/100,000). Similarly, AAs are 
1.42 times more likely to be deceased at age 65 and older (1,137.8/100,000) compared to 
European Americans (800.7/100,000).  
Cancer mortality potentially continues to increase worldwide with the potential to 
affect more than 13.1 million individuals by the year 2030 (WHO, 2012). Age is an 
extremely significant factor in the development of all cancers. In particular a greater than 
80% of CaP cases are diagnosed after 60 years of age (ACS, 2012; CDC, 2012).There is 
some concern that men in Asian countries could also be affected in their older decades 
despite the high level of soy intake in the diet, therefore adding urgency to this dilemma 
and disease burden (Thapa & Ghosh, 2012). Improved therapies and prevention strategies 
are therefore urgently needed. These strategies may help alleviate the increased disease 
burden experienced among various populations. Many lives are affected and myriads of 
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negative health issues accompany present therapies. More effective treatment strategies 
including chemoprevention would be beneficial.  
Although dietary intake of soy has increased in the U.S. over the past decades, 
evidence of quantity and frequency of consumption, and the group within the population 
that accounts for the highest dietary intake, remains uninvestigated. The appropriate 
dietary quantity and intake duration of soy or its extracted phytonutrients in relation to 
CaP chemoprevention are yet to be established. Randomized clinical trials have been 
designed to qualify intervention employing soy derived phytoestrogens (SDPs), but their 
examination is limited to studies which in most cases fail to yield significant and 
generalizable results (Venkitaraman et al., 2008). Epidemiological research has shown 
that there is 40 times greater consumption of soy in the Asian diet than consumed in the 
Western diet (Sharma et al., 2009). Understanding the effect that SDPs could have 
preventing CaP within the context of duration and concentration and more directly 
through serum levels of PSA and estradiol (E2) following dietary intake of SDPs is 
therefore prudent. Recent estimates indicate that CaP is now present among younger aged 
men within the population (ACS, 2012). This earlier onset of CaP incidence among 
younger aged men is further evidence of the need for novel preventive strategies or 
curative therapies.  
Phytoestrogens 
According to Ganry (2004), Morrissey et al. (2004), and Napora et al. (2011) 
SDPs, plant derived nonsteroidal compounds, are known to possess weak estrogenic 
properties. Food sources rich in these compounds include legumes and soy, with the latter 
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supplying an abundance of the SDPs in this study (CDC, 2012; Napora et al., 2011). 
Figure 1 provides information on both natural and synthetic SDPss and the end-product 
following ingestion and biochemical activity.  
 
Figure 1. Major phytoestrogens found in soy and the influence on PSA and estradiol.  
In addition to their chemoprotective properties, SDPss have the capacity to protect 
the prostate gland from tumor progression, and are important as anti-inflammatory 
compounds (Napora et al., 2011). SDPs are comprised of lignans, flavonoids, coumestans 
and isoflavones with the latter predominantly derived from soy (CDC, 2012; Strauss et 
al., 1998). Among isoflavones found in soy are genistein, glycitein and daidzein (Strauss 
et al., 1998), of which genistein and daidzein are the focus of this study. Genistein’s 
utilization is immediate within the body, while daidzein undergoes metabolism by 
bacteria in the gut (CDC, 2012). Daidzein’s convertion to O-desmethylangolensin, then 
equol and is the available estrogenic product (CDC, 2012).  
There are three main types of SDPss. Broad similarity exists between estrogens, 
isoflavones, and lignans, which comprise this group (BCERT, 2007). Lignans provide a 
major source of the consumed SDPs in the American based diet (BCERT, 2007). They 
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appear to have an inverse association with cardiovascular health (BCERT, 2007). 
Cancers have also been associated with some SDPs (BCERT, 2007). The established 
knowledge is that Asian based diets have a higher proportion of SDPs that correlate with 
a lower CaP incidence (Hsing & Devesa, 2001). An increase in the dietary levels of SDPs 
among men in the Western population could potentially provide beneficial 
chemoprotection. However, while genistein and daidzein are the major isoflavones found 
in soy, lignans make up the major polyphenols found in cereals, grains, some fruits, and 
vegetables. However, like daidzein, these lignans undergo conversion to other 
compounds by microbes found in the intestines, and newly formed compounds provide 
protection from some types of disease (Hsing & Devesa, 2001).  
Equol fermentation produces daidzein, while enterolactone and entereodiol are 
products of fermented lignans (Linus Pauling Research Institute, 2010). Compounds 
derived from lignans are possibly lacking in carcinogenic activity. However, lignan 
derived compounds are considered SDPs and when converted by bacteria can exert mild 
estrogenic effects (Linus Pauling Research Institute, 2010). Similar to SDPs, equol has 
also demonstrated cytotoxic activity against CaP cell lines, as does its lignan derived 
compound (Venkitaraman et al., 2008). Lignans exert their effect on cells including those 
within the prostate. This process could result in unwanted cellular differentiation and 
formation of precancerous lesions due to hypertrophy or hyperplasia (Venkitaraman et 
al., 2008). 
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Prostate Cancer and Phytoestrogens 
The reciprocal phytoprotection associated with an increase in incidence of CaP 
appears to be lacking in the US male population (CDC, 2010) and may simply be a 
reflection of the minimal quantity of SDPs consumed within the Western diet. Greater 
understanding of this association needs assessment. It is necessary to understand what 
factors are integral to any inferred chemoprotection to be able to understand the true 
effect of consumption within the target population. This encourages incorporation into 
the Western diet associated CaP etiological and subsequent preemptive model. This has 
resulted in the need to understand the association and to determine the exact effect size 
(ES) of intervention.  
CaP is considered hormonally controlled (Sekine et al., 2007; Ho, 2004). 
Predominantly, female hormones, E2 and estrone are the two major estrogen hormones 
secreted by the ovaries (NCI, 2012). The use of estrogens for CaP therapy has produced 
some positive results; however, concerns related to increase in hormone refractory cancer 
are valid. Hormonal therapy benefits include blocking of tumor growth, decrease of PSA 
levels and ability to use as adjunct therapy at any time other treatment modalities. The 
benefits of estrogen therapy have accompanying side effects. These side effects include 
impotence, weight gain and fatigue among others. Studies have shown that the delivery 
of estrogen through E2 skin patches can be effective in CaP therapy. Benefits also occur 
without some of the prior mentioned side effects such as impotence and weight gain 
(Strax, 2005). CaP is the most invasive tumor and ranks only behind lung cancer in 
mortality incidence among men (Agarwal, 2000; Bektic et al., 2003). Treatment of CaP 
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has focused on employing androgen deprivation therapy (ADT; Smith, 2007; Shahani et 
al., 2008) or orchidectomy (Singh et al., 2008). Increasing therapeutic use of ADT has 
been reported (Shahani et al., 2008; Singh et al., 2008; Smith, 2007). While these 
intervention processes have realized some benefits, some have also resulted in the 
development of unwanted events, including toxic conditions that can persist for extended 
periods (Lycette et al., 2006). Mitigating these unwanted events through new therapeutic 
agents including an increase in SDP intake. An increase in SDP intake is necessary, as 
there is some evidence of intake in the Western diet. However, this intake remains 
minimal in relation to that consumed in Asian diets.  
Employing ADT, as previously indicated, has been associated with adverse health 
conditions including osteoporosis, hot flashes, and changes in cognition (Basaria et al., 
2006; Cherrier et al., 2003). ADT therapy has been associated with the development of 
diabetes and other health conditions, which can influence other unwanted yet serious 
cardiovascular conditions (Napora, Short, Muller, et al., 2011). In fact, evidence 
implicates estrogen receptors (Härkönen & Mäkelä, 2004), as favorable to the 
development and progression of CaP. This conflicting report kindles the need to 
understand the context of ES. It also provides an opportunity to assess the true effect of 
studied SDPs in reducing or preventing CaP develo,pment or progression. Numerous 
epidemiological studies and in vitro experiments have demonstrated the chemoprevention 
benefits from SDPs (Kumar et al., 2011). It might therefore be plausible to assert that the 
chemoprotective influence of SDPs is the ability to regulate important receptor 
mechanisms. This subsequently results in a decrease in cancer development and 
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incidence. In fact, research by (Bektic et al., 2003), infers that genistein has an effect on 
ERβ and consequently a direct relationship on the down-regulation of those androgen 
receptors. ERβ has demonstrated its influence in tumor growth and proliferation 
(Härkönen & Mäkelä, 2004).  
Estrogens have remained important in the treatment of androgen-dependent CaP 
(Pendleton et al., 2008). The difficulty of treating CaP including hormone refractory 
disease continues to influence the search for novel agents for optimum therapy 
(Pendleton et al., 2008). Hormone refractory disease does not respond effectively to 
presently employed drugs (Cho, Di Blasio, Rhee, & Kattan, 2003). The thought is that 
greater than 20% of men who have been treated for androgen-dependent CaP will 
experience disease recurrence (Cho, Di Blasio, Rhee, & Kattan, 2003). This portends 
poor prognosis and decreased survivability. Present reports have indicated a greater 
survival rate of CaP diagnosed individuals because of the improved treatment methods 
and earlier diagnosis (ACS, 2012). Different levels of survival are reportedly associated 
with tumor stage with better outcomes when diagnosed as a localized tumor with almost 
100% survival (ACS, 2012). Distant metastases on the contrary are associated with 
approximately 29% survival (ACS, 2012). Treating metastatic and recurrent disease is 
therefore a health issue of paramount importance.  
Estrogens, Estradiol and CaP 
Estrogens, also known as oestrogens, are primarily female hormones. These 
estrogens have important value in areas including hormone replacement therapy (CDC, 
2012). They influence gene regulation because of their ability to diffuse across cell 
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membranes (CDC, 2012). Hormones that occur naturally in women include estrone (E1), 
estriol (E3), and 17β–estradiol (E2) with E2 observed as the predominant form (Ockrim, 
Lalani, Kakkar, & Abel, 2005). Although primarily synthesized in the ovaries of women, 
the discovery of estrogen receptors ER-alpha and ER-beta in the male prostate gland has 
increased some evidence of its value in the development of CaP (Ockrim et al., 2005).  
E2 is produced by the male reproductive system and is derived from testosterone 
(Ockrim et al., 2005). The connection between its serum concentration and SDP 
concentration might provide insight into the etiology of CaP. In fact, the androgen 
receptor appears to be the important target during prevention and treatment (Bonkhoff & 
Berges, 2008). Estrogen concentration is greatest in the male reproductive tract 
(Lombardi et al., 2001) resulting in the existing correlation between androgens and CaP 
proliferation (Morrissey et al., 2004). This understanding has resulted in reports 
suggestive of estrogen’s role in CaP etiology including a metabolic pathway association 
resulting in an associated genetic link (Bosland, 2005).  
The discovery of estrogen receptors, including possibly close correlation between 
a specific genetic polymorphism on ER-α and its link to the development of CaP, 
demonstrates a close relationship between estrogen and CaP (Bonkhoff & Berges, 2008; 
Bosland, 2005). In addition, the relationship between ER-β and CaP development is 
expressed through its down regulation in more malignant disease (Bosland, 2005) and 
during the progression of hormone-refractory disease (Bonkhoff & Berges, 2008). In 
addition, this ER-β relationship is observed in normal prostate tissue, benign prostatic 
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hyperplasia (BPH), and CaP, providing an opportunity for chemoprevention (Bonkhoff & 
Berges, 2008).  
Risk of Developing CaP 
While some cancers have experienced decline over the past decades, CaP 
continues to show an increase in incidence (NCI, 2012). In 2011, US estimates of CaP 
were approximately 241,740 new cases, with an expected mortality of 28,170 (NCI, 
2012). Those numbers are representative of the upsurge in CaP incidence from 2007 
when 223,307 cases were diagnosed in the US (CDC, 2012). However, compared to the 
estimated number of new cancer deaths that would occur based on 2007 data, the actual 
number of deaths (28,170) represent a slight decrease from 29,093 cases (CDC, 2012). A 
decrease in mortality from cancer is associated with an increase in early detection. 
As mentioned earlier, the risk of developing cancer increases with age. Figure 2 
illustrates the percent of U.S. men who developed CaP over various decades starting at 
age 30 through 70. At age 30, men have a relatively low risk of developing CaP with 
0.01% by the time they reach age 40, 0.32% at age 50 and 2.49% at age 60. However, the 
percentage of men currently age 40 and older who will develop CaP after 30 years 
increases proportionately to 8.30% of men by age 40, 14.40% by age 50, and 16.11% by 
age 60. At age 70, men have the same risk (8.50%) of developing CaP after 10 years than 
men currently aged 40 after 30 years.  
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Figure 2. Likelihood (%) of Developing CaP Over 3 Decades Based on Current Age, 
2005–2007. Source: Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, 
Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis 
DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER Cancer 
Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD, based on 
November 2009 SEER data.  
 
Problem Statement 
The disease burden of CaP among Western men is significantly greater than that 
observed among men in Asia, where soy is a dietary staple. While there has been 
extensive epidemiological research evidence supportive of the anticancer value of soy 
compounds among the Asian population, recent inclusion of SDPs in Western diet has 
not yet shown a noticeable reduction in disease incidence and outcome. Epidemiological 
evidence indicates soy based diets containing SDPs provide valuable chemoprotection. 
The threshold level of concentration and duration of soy based dietary intake contributing 
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to chemoprotection represents invaluable knowledge. Intake duration and concentration 
could help address the risk of CaP among high risk minority and other populations. This 
study addresses the problem of recurrence and identification of potential failure for any 
successful therapeutic intervention. Potentially, this research will provide evidence for 
further studies that could decrease CaP incidence and influence broad social change 
through improved health status and overall quality of life (QOL).  
Purpose of the Study 
The purpose of this study was to determine the ES of serum PSA and E2 levels 
following dietary genistein and diadzein intervention. Serum levels of PSA and E2 are 
important predictors of therapeutic response and disease outcome. Studying the response 
of PSA and E2 in American men and disease outcome has not previously occurred in that 
cohort. Guided by the principles of primary and secondary prevention and an original 
model of cancer prevention, the dual prevention intervention model, the study sought to 
answer whether intake duration and concentration of SDPs directly influence magnitude 
and direction of CaP response. Information for analysis in this study came from selected 
published randomized controlled trials (RCTs) of SDP intervention designed to prevent 
or delay recently diagnosed CaP, increasing PSA and hormone refractory CaP in men 
between 50–85 years old.  
Theoretical Base: Dual Prevention Intervention Model 
The theoretical base for this study has roots in one of the recognized multistep 
models of development of neoplasia or tissue growth arising from the biological sciences. 
The putative multistep pathway model (Giovannucci, 1999) provides evidence for the 
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indication of chemoprevention through SDPs. Giovanucci’s model was structured on the 
premise that intake levels of SDPs are associated with the lower incidence of CaP 
observed among men in Asian countries. CaP carcinogenesis through the presence of 
increasing PSA is one of the mechanisms depicted in this model as early evidence of 
damage to the normal prostate tissue resulting from genetic mutation and cellular 
damage. Biological models do not focus on the principles of primary cancer prevention 
and control and the approach to disease prevention has unfortunately reflected this 
premise in that screening for CaP is a secondary prevention effort aimed at detecting 
increasing PSA. At the same no new biomarkers to detect changes in the normal prostate 
tissue have been discovered or suitable for use at a population level.  
The strategy of the dual prevention intervention model (DPIM) is to present an 
original contribution to the field of public health that aims to avert early prostate tissue 
damage (Michelin & Gutierrez, 2013). Figure 3 depicts the premise of the DPIM 
conceptual model, which posits that the development of CaP and other cancers result 
from continued interaction to environmental and biological exposures. Over time, these 
exposures result in cellular changes from stress and resulting mutations that may occur 
with prolongued exposure. Beyond the multistep causative mechanisms, the DPIM has 
identified critical points at which a public health primary prevention approach through 
phytochemical intervention and a potential therapeutic intervention through secondary 
prevention can be implemented in high risk populations such as African Americans. The 
primary prevention component of the DPIM recognizes that other theoretical models 
proposed in the literature focus on the identification of mitigating factors that result in 
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cellular biological changes. These activities lead to the development and progression of 
CaP. Preventing or delaying cellular biological changes that result in CaP development 
and progression is the focus of the DPIM.  
The goal of this research is to prevent, delay, or reverse disease through dietary or 
medicinal addition of SDPs to avert development and progression of prostate tumor. 
Mitigating factors such as age, inflammation, change in hormonal status and genetic 
mutations is of valuable importance to this process. While several studies have provided 
scientific support for events that describe such association (Wang, Clubbs, & Bomser, 
2006), the true ES of SDP intervention on individuals at various stage, grade or type of 
CaP has not been completely analyzed and presented in the present literature. While the 
model by (Giovannucci, 1999) provided for later androgen deprivation therapy (ADT) 
and other chemotherapeutic agents for treatment, the DPIM focuses on the identification 
of a critical point for primary prevention intervention. The broader scope of the DPIM is 
shown through this meta-analysis that showed the true ES of SDP intervention. The 
research revealed the much desired importance of secondary prevention using SDPs 
inclusive of E2 therapy. The study result showed that decrease in serum PSA 
concentration was a desired outcome from SDP intervention.  
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Figure 3. Dual Prevention Intervention Model (DPIM). Michelin & Gutierrez, 2013, n.p. 
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Nature of the Study 
The study was a quantitative analysis of data from published randomized-
controlled trials (RCTs) demonstrating the chemoprevention ability of soy and its derived 
SDPs. The population sampled included men ages 50-85 in the United States. The studies 
were analyzed employing meta-analysis. The independent variables were dietary 
quantities of the SDPs genistein and daidzein. The dependent variables included serum 
levels of E2 and PSA. I sought to determine the ES in SDP dose-response intervention in 
selected male populations during the therapeutic application for recently diagnosed and 
recurrent CaP, and the contribution of duration and concentration in determining the size 
and direction of action. The principles of primary and secondary prevention and the 
original conceptualization of the DPIM of cancer prevention guided this research study. I 
sought to answer whether intake duration and concentration of SDPs directly influence 
magnitude and direction of serum PSA and E2 during various conditions of CaP disease. 
I conducted a statistical analysis employing CMA specialized software to determine the 
ES using Odds Ratio statistic and the REM. Odds Ratios were calculated through 2x2 
contingency tables. Confirmatory analysis included Cohen’s d, Q statistic, and mean 
standardized differences. Heterogeneity was measured using g statistic. (More details 
provided in Chapter 3). 
Research Questions and Hypotheses 
The ingestion, duration, and concentration of SDPs are responsible for the 
associated lower incidence of CaP and other prostate diseases observed among Asian 
males (Dalais et al., 2004). Inversely, its decreased intake among men in Western 
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countries appears to be associated with a higher incidence of CaP and other prostate 
diseases. Answering the research questions provided some perspective on the effects of 
different independent variables on dependent variables and subsequently on disease 
outcome among men in Western countries. I sought to answer the following questions:  
Research Question 1: Is there a correlation between dietary SDPs and serum SDP levels? 
Null Hypothesis H1o: There is no correlation between dietary SDP levels and 
serum SDP levels. 
Alternative Hypothesis H1A: There is a correlation between dietary SDP levels 
and serum SDP levels.  
Research Question 2: Is there a correlation between dietary SDP levels and serum PSA 
levels?  
Null Hypothesis H2o: There is no correlation between dietary SDP levels and 
serum PSA levels. 
Alternative Hypothesis H2A: There is a correlation between dietary SDP levels 
and serum PSA levels.  
Research Question 3: Is there a correlation between dietary SDP levels and serum E2 
levels?  
Null Hypothesis H3o: There is no correlation between dietary SDP levels and 
serum E2 levels.  
Alternative Hypothesis H3A: There is a correlation between dietary SDP levels 
and serum E2 levels.  
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Research Question 4: Is there a correlation between serum SDP levels and serum PSA 
and serum E2 levels?  
Null Hypothesis H40: There is no correlation between serum SDP levels and 
serum PSA levels.  
Alternative Hypothesis H4A: There is a correlation between serum SDP levels and 
serum PSA levels.  
Research Question 5: Is there a correlation between serum SDP levels and serum 
E2 levels? 
Null HypothesisH5o: There is no correlation between serum SDP levels and serum 
etradiol levels. 
Alternative HypothesisH5A: There is a correlation between serum SDP levels and 
serum E2 levels.   
Definition of Terms 
Androgen deprivation therapy (ADT): Treatment that is used to block or suppress 
the production or action of the male hormones known as androgens. This is achieved by 
either removal of the male testicles, or blockage with female hormones or drugs called 
antiandrogens. This type of therapy is also referred to as androgen ablation or androgen 
suppression (NCI, 2012).  
Benign prostatic hyperplasia/Benign Prostatic Hypertrophy (BPH): A non-
cancerous condition which involves an excess growth of prostate tissue that pushes 
against the urethra and the bladder resulting in a blocking of normal urine flow (NCI, 
2012).  
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Cancer recurrence: Cancer which has returned after a period of time in which the 
cancer was unable to be detected. This cancer might return to the same place as the 
previous tumor but could also return to a different region of the body (NCI, 2012).  
Chemopreventive: The use of drugs, vitamins, and other compounds to try and 
reduce the risk of development, recurrence or progression of cancer (NCI, 2012).  
Chemoprotective: The quality displayed by some drugs used for treating cancer. 
The chemoprotective agent protects the healthy tissue from the toxic effects of drugs used 
during cancer therapy (NCI, 2012).  
Chemotherapy: The killing of cancer cells using drugs (NCI, 2012).  
Diagnosis: “the process responsible for identification of a disease such as cancer 
from its sign and symptoms” (NCI, 2012).  
Daidzein: An isoflavone fond as a biochemical component of soy (NCI, 2012). 
Disease incidence: The number of new cancer cases over a specific period of time 
which is usually recognized as one year.  
Distant metastasis: This is a reference to cancer that has spread from the primary 
tumor to distant organs or lymph nodes. Also related to as distant cancer.  
Digital Rectal Examination (DRE): A procedure in which a trained medical 
practitioner performs a digital examination of the prostate employing appropriate and 
established medical practice (NCI, 2012).  
Double-blind: A clinical trial in which the medical staff, the patient, and the 
people who analyze, the results, do not know the specific type of treatment the patient 
receives until the trial has been completed (NCI, 2012).  
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Isoflavones: Nonsteroidal plant derived phytoestrogen compounds which can bind 
the estrogenic receptors and can affect the normal estrogen regulation process (NCI, 
2012).  
Effect size: This is considered a numerical way of assessing the strength or 
magnitude of a reported relationship even it is seen as casual or otherwise (Villanova 
University, 1984).  
Epidemiology: According to the WHO (2012), epidemiology is the study of the 
distribution and determinants of health-related states or events which includes diseases 
and the use of epidemiological practices to control these diseases and other health 
conditions.  
Estrogens: Any of several major female sex hormones produced primarily by the 
ovarian follicles of female mammals, and capable of inducing estrus (oestrus), 
developing and maintaining secondary female sex characteristics, and preparing the 
uterus for reception of a fertilized egg. It is used especially in the synthetic form as a 
component of oral contraceptives in certain treatments and other forms of therapy (NCI, 
2012).  
Etiology: “the origin or cause of disease” (NCI, 2012).  
Fixed Effects: The assumption that there is only one true effect size 
(Wiley/ITMA, 2009).  
Genistein: An isoflavone found as a biochemical component of soy (NCI, 2012).  
Gleason Score: According to the (NCI, 2012), Gleason score is the system 
presently employed to grade CaP tissue in context to how it appears when viewed 
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microscopically. The Gleason score ranges from 2 through 10 and is a reflection of the 
likeliness of the tumor spreading to adjacent tissues. Lower Gleason score indicates a 
decreased likelihood of the tumor spreading while a higher Gleason score is indicative of 
tumor with greater likelihood of spreading. It also demonstrates a higher variability from 
normal prostate tissue.  
Hormone Refractory Disease/Hormone Resistant Disease (HRD): A disease 
condition that does not respond to hormone therapy (NCI, 2012).  
Morbidity: Relates to a disease or incidence of disease within a population. It also 
refers to the adverse effects resulting from a treatment (NCI, 2012).  
Mortality: A reference to the death rate which is also the number of deaths in a 
particular group over a specific period of time. Mortality might also be reported for 
people with a particular disease, live in one area of the country, and who belong to a 
certain age, gender, and ethnicity (NCI, 2012).  
Outcome: “an effect that is measurable or a specific result. Examples of outcomes 
include decreased pain, reduced tumor size, and the improvement of disease” (NCI, 
2012).  
Phytoestrogens: Morrissey et al. (2004) indicated that phytoestrogens are 
considered nonsteroidal compounds derived from plant sources and which have 
estrogenic activity. 
Prognosis: This is the likely outcome or course of a disease but can also be 
defined as the chance of recovery from a disease or recurrence of the disease (NCI, 
2012).  
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Prostate Specific Antigen (PSA): A protein substance that is produced by the 
prostate gland and when found in the blood at a higher level than considered normal 
might be an indication of CaP, BPH, inflammation or infection (NCI, 2012).  
Prostatic Intraepethelial Neoplasia (PIN): Noncancerous growth of the cells 
lining the internal and external surfaces of the prostate gland. Having high-grade prostatic 
intraepithelial neoplasia may increase the risk of developing CaP. (NCI, 2012). 
Prostatitis: Considered inflammation of the prostate gland (NCI, 2012). 
Radical prostatectomy: A surgical procedure that removes all of the prostate 
gland and some of the surrounding tissues (NCI, 2012). 
Radiotherapy: Also called irradiation or radiation therapy. Involves the use of 
various high-energy radiation sources including x-rays, gamma rays, neutrons, protons 
and other sources to destroy cancerous cells and shrink tumor. Radiation can be from an 
internal source placed near the cancer cells or from an external source where beams were 
directed against the cancer cells. In systemic radiotherapy, the source is radiolabeled 
monoclonal antibodies that reach tissues after traveling through the blood (NCI, 2012).  
Random Effects: The assumption that the true effect could vary from one study to 
the next (Wiley/ITMA, 2009).  
Randomized Clinical Trial: A study in which the participants are assigned by 
chance to separate groups that compare different treatments; neither the researchers nor 
the participants can choose which group. Using chance to assign people to groups’ means 
that the groups will be similar and that the treatments they receive can be compared 
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objectively. At the time of the trial, it is not known which treatment is best. It is the 
patient's choice to be in a randomized trial (NCI, 2012).  
Receptors: Structure on cell surface or inside cell that selectively receives and 
binds a specific substance (MedicineNet, Inc., 2012).  
TRAMP mice: Transgenic adenocarcinoma of the mouse prostate (Hurwitz, 
Foster, Allison, Greenberg, & Kwon, 2001).  
Assumptions 
This study is based on several major assumptions. The first assumption is that the 
lower incidence of CaP observed among Asian men is attributable to the greater intake of 
dietary soy derived SDPs/isoflavones namely genistein and daidzein (Willis & Wians, 
2003). The second assumption implies that the resulting metabolic changes from SDP 
intake produce bioactive compounds linked to this lower incidence of prostate diseases 
observed within the Asian male population (Bektic et al., 2005; Kumar et al., 2011). The 
third assumption was that that an increase intake of soy derived dietary isoflavones 
among men in Western countries would result in a decrease in CaP incidence. The fourth 
assumption was that the beneficial changes in CaP are associated with serum, a decrease 
in serum PSA level, and an increase in serum E2 level. The fifth assumption was that a 
reduction in disease incidence would result in beneficial health outcomes within the 
western male population and reduce the disease and economic burden associated with 
disease treatment and management. The sixth assumption was a reduction or elimination 
of potentially unnecessary screenings, treatment, and a reduction of valuable quality of 
life issues that are associated with care and management of the disease. The seventh 
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assumption was that the employment of meta-analysis will mitigate differences in and 
between studies and provide statistical relevant ES information. The eighth assumption is 
that if findings demonstrate a positive correlation to E2 and inverse relationship to PSA 
response then further exploration of therapeutic or chemoprevention explored for other 
hormonal driven cancers including breast and ovarian cancers. The ninth assumption was 
that the variables had the potential to influence the outcomes and subsequent data 
presented in the analysis. Finally, evidence from this meta-analysis examination used to 
establish recommended daily dietary value for these studied SDPs.  
Limitations 
The following limitations were anticipated. This meta-analysis used data of prior 
research from selected published RCTs. These output data included the use of already 
established methods of data collection. The strategies employed in those prior analyses 
and the evidence presented from those studies is not amenable. These data are an 
accumulation of output data from other studies that included subjects who are different 
demographically, in age, in ethnicity, and socioeconomic status, possibly with numerous 
different health backgrounds. There is also the issue of reliability of the information 
source since it is difficult to monitor if diets consumed consisted of the soy products that 
are associated with the studied chemo-protective activity. Limitations also included the 
inability of the researcher to define criteria for selection as these were already determined 
by the RCT process. An important limitation relates to the coding, or data extrapolation 
process, as this process requires proper monitoring to ensure correct information 
retrieval, then the effect size values regarding the treatment outcomes would be incorrect. 
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Another limitations might also be present in the selection process used to recruit subjects 
for the different studies. Several conditions including age, health history and weight of 
participants were possibly important confounders and therefore, could have a negative 
influence on the produced output data. 
Delimitations 
The following were delimitations in this study. The role of environmental, 
genetics, and other exposure factors can be important delimiting factors. Factors 
contributing to the initial onset of prostate disease are observed through prostate 
intraepithelial neoplasia (PIN) development following extensive exposure. Delimitations 
might also be evident in the method of analysis been employed to determine the true 
effect of duration on the chemo preventive role of SDPs.  
Significance of the Study 
The dynamics of the interaction between phytoetsrogens, tumor development, 
proliferation, prevention, and even recurrence are valuable to greater understanding of 
implementation of workable intervention strategies. It is through understanding of the ES 
from research evidence that strategies can be developed, novel therapies implemented 
and, further research pursued that could help improve health outcomes. Information 
might also be important in its role of decreasing CaP disease incidence in populations that 
are considered at greater disease risk. There is not only an economic burden but also the 
social and psychological experiences of those affected by CaP (Turner et al., 2009). An 
event that can reduce the impact of social and other burden on the individual, the family 
and the wider supportive family of social network, would be valuable. Therefore, 
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addressing issues of quality of life (QOL), physical and mental strain, and improving the 
broader outlook associated with survivability and improved health outcomes (Sharpley, 
Bitsika, & Christie, 2011; Turner et al., 2009). Understanding how CaP impacts those 
affected and those in the broader community through greater awareness are also 
important concepts that the study addressed. With CaP considered a disease that will 
increase as the male population gets older and there is a greater possibility, of the 
incidence of CaP, than any intervention that could reduce such incidence including the 
tremendous economic and health burden that is associated would be of tremendous social 
value. In the social context, there would also be a greater desire to have soy products 
become a dietary staple. This could change the present outlook of the disease within the 
more at-risk communities and importantly among the populations now experiencing 
higher incidence.  
This study is significant in that it presents an original contribution to the field of 
public health that aims to avert early prostate tissue damage through identification of a 
critical point at which a primary prevention is incorporated. The goal of this research and 
the DPIM (Michelin & Gutierrez, 2013) is to prevent, delay, or reverse disease through 
addition of SDPs either dietary or medicinally to avert progressive development of 
prostate tumor. While several studies had provided scientific support for the events 
describing such association, in this study, I analyzed relevant literature and determined 
the true ES of SDP intervention on individuals with various stage, grade or type of CaP. 
Through the broader scope of the DPIM, the meta-analysis of the true ES revealed the 
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much more important secondary preventive role of SDPs through E2 therapy compared to 
expected decreases in PSA as the desired outcome.  
Summary and Transition 
Chapter 1 provided an overview of CaP in the US population. There is need for 
examination of the shortfalls regarding the present therapeutic practices. How these 
reflect the need for novel therapies for improved health outcomes. Some relevant 
discourse is presented based on the studies employed in this meta-analysis and how this 
present a worthy context to the research focus regarding the employment of various soy-
based products for CaP therapy or prevention. This is important not only in context to 
complementary and adjuvant therapy but as the defining therapeutic intervention process. 
Chapter 2 will be devoted to the review of supportive literature that will offer scientific 
insight and knowledge base. This information will span a vast array of material 
incorporating theoretical and experimental discourse and providing even greater 
understanding and relevance to the various aspects of the disease process. The study 
discusses potential benefits of SDPs for therapeutic intervention in combating the 
incidence of CaP. Chapter 3 is a detailed presentation of the research methodology which 
relates to ES, and importantly how this is demonstrated employing either an open- or 
fixed-effect model analysis. However, in this study, I used the REM for ES analysis. 
REM represents a more precise evaluation of the aim and objectives of this study. The 
assumptions will support or offer a clear relationship between SDPs and their value in 
helping to reduce CaP. The debilitating effects of CaP remain in ethnic populations still 
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affected by higher disease incidence. These populations continue to experience greater 
disease burden than the male population in Asian countries. 
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Chapter 2: Literature Review 
Overview 
The purpose of this study was to determine through OR meta-analysis the ES of 
genistein and daidzein on PSA and E2 serum levels. The magnitude and direction of that 
response to dietary and then serum genistein and daidzein levels will also be determined. 
The influence on both PSA and E2 serum levels could be valuable in determining 
treatment outcomes in diagnosed CaP cases, rising PSA, and HRCaP. The effect of 
dietary and serum SDPs on PSA and E2 serum levels has not previously undergone 
analysis in this cohort of American men. The chapter has several sections. These include 
the literature search strategy, background of prostate and hormone refractory cancer, 
epidemiology and pathophysiology of CaP, theoretical base and theoretical applications 
of CaP and SDPs, E2, and PSA. Literature on differing views and methodology related to 
RCTs involving chemoprevention intervention is also included. There is also a 
concluding summary of the chapter and transition to Chapter 3. 
Literature Search Strategy 
Conducting a review of pertinent literature involved extensive search of Science 
Direct, SciVerse, PubMed, and Walden University’s online library. Search terms used 
included phytoestrogens and cancer therapy, phytoestrogens and prostate cancer, 
genistein and cancer therapy, and several combinations of terms that included either 
prostate cancer, genistein, daidzein, and/ or phytoestrogens. The articles selected for 
analysis in this study were selected following a search of Science Direct, SciVerse and 
PubMed using a collection of terms that included phytoestrogens and prostate cancer 
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therapy. The selected studies also had to include the terms of randomized-controlled 
double-blinded clinical trials, which employed either genistein and/or daidzein as 
included elements of the study process. 
Prostate and Hormone Refractory Cancer 
CaP including HRCaP (Crawford, 1992; Sadar, Hussain, & Bruchovsky, 1999) 
follows surgical castration or disease not responding to androgen deprivation therapy 
(ADT; Napora, et al., 2011; Sharifi, Gulley, & Dahut, 2005). It accounts for over 10% of 
cancer cases, and is expected to fail all present therapies. The subsequent recurrence is 
associated with poor health outcomes as a consequence of this difficulty to treat the 
resulting disease (Singh, Matanhelia, & Martin, 2008).  
While results might be somewhat unpredictable, evidence suggests that use of 
secondary hormonal therapy could provide some health benefit (Pendleton et al., 2008; 
Ryan & Small, 2003). This perspective can be relevant when appreciating the dietary 
intake of SDPs. Intake of SDP is estimated to be 60 times greater within the Asian 
population than among Western men (Qin et al., 2003; White et al., 2004). Several 
researchers, including Adams et al. (2004), Boyle, Maisonneuve, and Napalkov, (1995), 
and Hsing and Devesa, (2001), have also acknowledged that there are health benefits that 
can be attributed to the intake of SDPs. These include a difference in the incidence of 
prostate diaseases observed among Asian men who have immigrated to Wetsern 
countries (Adams et al., 2004;  Boyle, Maisonneuve, & Napalkov, 1995; and Hsing & 
Devesa, 2001). Some context to potential health benefits of SDPs also relates to the 
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observations made regarding the detection of isoflavones in the serum of newly born 
babies (Adlercreutz, Yamada, Wahala, & Watanabe, 1999).  
This implied evidence of chemoprotection provides the opportunity for 
complementary and alternative modalities (CAM) to be implemented as intervention or 
proposed treatment strategies (White et al., 2004). The inclusion of SDPs and other SDPs 
into the Western diet has not seen similar lowering of CaP incidence. This observation 
suggests that CaP and other prostate diseases are still been defined by a higher incidence 
rate among Western men. Globally, the most prevalent cancers include prostate, lung, 
colorectal, stomach, and breast cancer (WHO, 2012). Significantly, in regions surveyed 
by the WHO, the report implies that the highest incidence occurs in Europe and the 
Americas (WHO, 2012). However, the lowest observed incidence is in Southeast Asian 
countries where SDPs are an important dietary staple (WHO, 2012).  
Hormonally influenced cancers include CaP, ovarian, and breast cancers. These 
cancers affect millions globally. The concerns regarding response to present therapies 
have resulted in the need for complementary modalities such as herbal and enzyme 
therapies, hydrotherapy, and the use of soy-derived components including the isoflavones 
genistein and daidzein (Auerbach, 2006). These have shown the potential to elicit 
positive therapeutic response (Auerbach, 2006). The lack of information regarding the 
etiology of HRCaP from initially-treated cancer that had responded to therapy, has also 
been demonstrated through in vitro analysis and expression of the androgen receptor 
Ki67, receptor BCAR and decreased staining of 5α-reductase, aromatase and estrogen 
receptor β (Celhay, Yacoub, Irani, et al., 2010). Evidence suggested that during relapse 
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there appeared to be a lower expression of estrogen receptor α which was also inversely 
proportional to the proliferation of tumor cells (Celhay, Yacoub, Irani, et al., 2010). 
Therefore, progression from a disease that initially responded to hormone therapy and 
subsequently fails to respond presents an important point regarding the issue of 
recurrence and tumor progression (Celhay, Yacoub, Irani, et al., 2010).  
The concern of finding an appropriate model for research is also still an issue. 
Hypothetical models such as the oxidative stress model by Thapa and Ghosh (2006), and 
the putative multistep model by Giovannucci (1999), which is the model followed by this 
research, provide some context to the development of the disease and opportunity for 
therapy and chemoprevention. However, the benefit of the mammalian model is tied to 
the relationship between species and is suggestive of some parallels in the etiology of the 
disease. Certain phases of the mammalian model have shortfalls, which underscores the 
complex development and progression associated with CaP. Antioxidants are found 
predominantly in fruits and vegetables and also viewed as important anticancer agents. 
This antioxidant involvement in reducing the inflammatory process is among the 
important benefits and anticancer activity of soy derived SDPs (Borek, 2005).  
These sections provide an attempt to understand these associations with CaP 
etiology and how these complex events can be understood within the context of SDP 
intervention. Understanding the complex CaP models that provide additional background 
regarding the multifaceted development of the disease and including the significant role 
of estrogen in its etiology is also valuable. Problems relating to disease recurrence 
following ADT and surgical castration provide some insight into the complex 
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management problems. Poor outcomes appeared to be associated with a decreased 
expression of the estrogen receptor ∞ and what is considered high proliferation index 
(Celhay, Yacoub, Irani, et al., 2010). With CaP considered a disease, where the risk 
factor and incidence increases with age, then understanding the value of SDPs as a 
preventive or curative option, will be important. In fact, there appears to be some 
credence afforded to this thought, with the evidence suggesting that men who had 
developed a westernized lifestyle following migration and included lifestyle changes 
subsequently also had an increased risk of CaP development (Haenszel & Kurihara, 
1968; Staszewski & Haenszel, 1965; Wang, Clubbs, & Bomser, 2006).  
Evidence presented through findings from in vitro studies (Wang, Clubbs, & 
Bomser, 2006), also indicates the important role of genistein in the signal regulation of 
estrogen. Genistein is one of the isoflavones that is of interest to this study. Human 
studies have also demonstrated the chemoprotective value of SDPs with focus placed on 
the soy derived isoflavones genistein and diadzein that are soy derived. The effect of 
these compounds in alleviating the disease burden in the population is a focus of this 
dissertation and will be analyzed employing meta-analysis of data from representative 
selected randomized trials that will reveal the true ES of these SDPs on CaP within the 
population. The result of either being preventative or curative in relation to CaP will be 
defined following analysis of intake duration. This will demonstrate their ability to 
significantly assist in reducing the present burden in prostate disease now experienced 
among males in Western countries when compared to that experienced among males in 
Asian countries.  
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Epidemiological data appear to indicate the presence of SDPs in neonates 
following birth from mothers known to have consumed high quantities of SDP in the 
diets (Adlercreutz, Yamada, Wahala, & Watanabe, 1998). Presentation has been made on 
the available understood natural history of CaP, including the screening methods and 
subsequent tests that are employed in establishing a positive diagnosis. Present theories 
that have been established in relation to hormone refractory disease, the success and 
failure of presently available drugs for disease treatment, and the continuing trend of 
employing SDPs, and significantly those associated with soy products which have 
experienced a continuing upsurge in use over the past decades.  
CDC (2012) data indicate a trend that acknowledges a statistical decrease in 
disease incidence within the US population. However, trends appear to be different from 
those provided by the World Health Organization (WHO). Reports indicate an increase in 
cancers and globally cancer related mortality is predominantly from five cancers 
including CaP (WHO, 2012). However, while significant decrease in cancer incidence is 
represented by a total 1.6% among the US population, data indicate only minimal 
reduction in CaP (CDC, 2012). Disproportionately, the incidence rates remain higher 
among minority populations, and African American men record the lowest annual 
decrease of 1.7% between the years 1998 to 2008 (CDC, 2012). There is need to 
appreciate the value of these WHO supported reports. WHO (2012) also detailed the 
significance of CaP in various geographical regions, with greater incidence in the 
developed economies (WHO, 2012).  
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Improved medical therapies and improved diagnostic tools have not resulted in a 
significant decrease in incidence among CaP and other prostate maladies experienced by 
men in Western countries. Evidence from several epidemiological studies have also 
shown an increase in CaP cases among men in Western countries with annual incidence 
and mortality rates greater than 200,000 and over 20,000 respectively (Jemal et al., 2009; 
White et al., 2010). Hormones are known to influence the growth and proliferation of 
prostate tumor cells (Bonkhoff & Berges, 2009; Harkonen & Makela, 2004; Lombardi et 
al., 2001; Qin et al., 2003; Singh et al., 2008; Weihua et al., 2002). However, hormone 
independent CaP accounts for a vast number of disease recurrences, even in men who 
have undergone radical prostatectomy/surgical castration (Chang, Cheng, Huang et al., 
2009). There is also evidence that PSA levels can rise independent of prostate disease 
(Ito, Yamamoto, Ohi, et al., 2003), which can also complicate any true dependence on 
PSA levels as a reliable indicator of either disease progression or limitation.  
This disease is not only difficult to treat, but does not respond to several of the 
present therapeutic agents and is marked by poor prognosis and disease outcomes. A 
beneficial role of dietary SDPs has been proposed for hormonally dependent diseases 
(Strauss et al., 1998). The work by Hamilton-Reeves, Rebello, Thomas, Slaton, and 
Kurzer (2007) implies that intake and duration of soy components possesses protective 
capability for men with high risk of developing CaP. This protection was due to a 
lowering of serum hormones including E2 from ingested soy proteins and therefore seen 
as beneficial to the deterrence of CaP (Hamilton-Reeves et al., 2007), probably through 
estrogenic and antiestrogenic effects, and enzymatic and other nonhormonal factors 
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considered important to the actions (Strauss et al., 1998). In Asian men where soy based 
diet is a staple, there appears to be a lower incidence of CaP and various prostate 
diseases. Understanding the strength of the association between SDPs and preventing 
CaP is important to initiating a prevention program. 
Previous in vitro work by Fotsis et al. (1995), Onozawa et al. (1998), and Shao et 
al. (1998) has demonstrated the PSA lowering ability of this SDP. A study by (Sharma et 
al., 2009) also appeared to corroborate phytoprotective ability through improved quality 
of life (QOL) indicators for cognitive and erectile dysfunction issues. Others were not 
improved in androgen deprivation therapy (ADT) treated subjects (Sharma et al., 2009). 
The (ACS, 2012; CDC, 2012) implied that these problems can be attributed, to the 
extensive utilization and quite often, unnecessary use of medical treatment for prostate 
diseases. There is also significant disease recurrence following radical prostatectomy, 
hormone treatment, radiotherapy, chemotherapy and other adjuvant therapies (ACS, 
2012; CDC, 2012). Importantly, and certainly invaluable to the foundation of this study is 
the fact that epidemiological evidence points to no distinguishable tumor present in male 
chimpanzees that primarily consumed plant based diet containing lignans and SDPs 
(Fuhrman, 2012; Musey et al., 1995). These compounds are attributed to the almost 
nonexistent cancer incidence and burden in these mammals (Fuhrman, 2012; Musey et 
al., 1995). While early diagnosis offers tremendous opportunity for effective treatment 
and ≥ 99% survival, the lack of a reliable therapy and a method for early diagnosis, 
presents some concern. The slow growth of some tumors also allow for what is 
considered surveillance or watchful waiting (WebMD, 2012). A scheduled surveillance 
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allows for implementation of the most suitable therapy (WebMD, 2012). In fact, 
uncertainty remains regarding the appropriate time for androgen therapy, and concerns 
regarding associated side effects from testosterone suppression include osteoporosis and 
reduced QOL (Vaishampayan et al., 2007). QOL certainly becomes a major issue during 
CaP therapy. In fact, individuals who are diagnosed with metastatic disease where 
survival is highly reduced remain a group that needs access to more effective therapy. 
Treatment should be geared to increasing survival and improving QOL. There is also 
need to understand the antioxidant capacity SDPs (DiSilvestro et al., 2006), though there 
is already established support of antioxidant relationship to cancer prevention (Borek, 
2005; Collins, 2005; Czernichow, Thapa & Ghosh, 2012; Galan, & Hercberg, 2005 
Jayaprakash & Marshall, 2011). Earlier prevention could avert more complicated 
progressive disease conditions.  
Reliability and sensitivity concerns also plague the PSA test, which is still 
employed as a primary diagnostic tool (ACS, 2012; CDC, 2012). The test is also 
important in the follow-up process for disease response during therapy, and as the 
precursor process to the digital rectal examination (DRE) and other diagnostic tools 
(ACS, 2012; CDC, 2012). Consequently, a reduction in PSA level in response to SDP 
intake, while valuable for disease response, can demonstrate even more value if the 
statistical analysis corroborate and complement survival and better health outcomes. The 
association between SDP intake and decreased PSA is also important in future analysis 
regarding lower incidence rate in those high-risk populations. Also important is 
recognition that the reliability and specificity of the PSA test still seem inadequate, since 
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the present cut-off value of 4ng/ml can be unreliable in confirming CaP. Lowering the 
value to 2.5/3.0 ng/ml, especially in younger males has therefore, been proposed 
(WebMD, 2012). Some beneficial association is evident regarding the influence of SDPs 
on PSA during less advanced disease, although demonstrating diminishing correlation 
(White et al., 2010).  
Another concern relates to prostate diseases affecting younger men and not only 
men in the later decades, where mortality might be attributable to other diseases (CDC, 
2012). Again, the need for more reliable therapeutic and preventative interventions 
should therefore be paramount. Disease recurrence is also anticipated among five percent 
of all those affected by CaP (ACS, 2012). With age considered possibly the greatest risk 
factor, prevention is certainly a prudent strategy.  
BPH, introduced earlier, does not necessarily imply progression of CaP. However, 
an association has been established and, prevention of BPH through SDP intake might 
significantly reduce this problem including the potential for further disease initiation 
(Lee, Gomez, Chang, et al., 2003). Both BPH and CaP have been acknowledged as 
having lower incidence among Asian men, among whom ADPs is a dietary staple. It is 
this protective role that appears to be important in the lower incidence of prostate 
diseases such as BPH and CaP among Asian men. It is important to determine the 
consumption practices of those products that can benefit the health of men in Western 
countries.  
CaP risk is still evident even after orchiectomy or androgen ablation to surgically 
inoperable cancer as development of resistance usually occurs within months or a few 
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years (Singh et al., 2008). This development of androgen-insensitive tumors usually has 
poor prognosis and decreased survivability (Singh et al., 2008). CaP is a very complex 
disease and management with the aim of effecting long term curative outcome, is still a 
very difficult situation. There is still uncertainty about the etiology of CaP although 
evidence points to continuous mutation of abnormal cells that subsequently proliferates 
and metastasizes (Mayo Clinic, 2011). The potential for SDPs in a preventative context 
therefore, appears quite prudent. Information from several randomized-controlled studies 
implies further benefits through the reduction of PSA than other biochemical responses. 
Estrogen therapy remains widely employed and continues to be associated with concerns, 
including possible involvement in influencing CaP growth and proliferation (Bonkhoff & 
Berges, 2009; Celhay et al., 2010). SDPs therefore, appear to be multifaceted in their 
ability to provide chemoprotection to prostate gland cells (Guy et al., 2012; Hsing, Tsao, 
& Devesa, 2000). The added biochemical characteristics of SDPs as an antioxidant might 
certainly be important in the displayed chemoprotective ability (Borek, 2005). Among 
biological concepts that have been studied are modifications on the androgen receptor 
(AR) gene through mutation or amplifying activities, and phosphorylation of AR protein 
(Celhay et al., 2010).  
Epidemiology of Prostate Cancer 
While 1 in 6 males are diagnosed with CaP, approximately 2.5 million that have 
been affected are among present CaP survivors in the USA (ACS, 2012). In 2012, 
mortality from CaP is estimated at 28,170, with nearly 241,740 males among those newly 
diagnosed (ACS, 2012). In fact, CaP accounts for the second highest cancer incidence 
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rate among US males and was responsible for over 33,720 deaths in 2011 (ACS, 2011). 
Although there is a decrease in incidence, there remain the need for improved therapies 
and effective prevention strategies. This is especially significant since the disease appears 
to affect at an average age of 67 (ACS, 2012).  
While the disease has a higher incidence in males in Western countries, compared 
to those in the Asian male population, pathological data indicates similar incidence of 
latent disease, in approximately 80% of males ≥ 80 years old (Kumar & Anderson, 2002). 
This lower incidence mentioned among males in the Asian population has been 
associated with the potential protective activity of SDPs consumed in the diet of Asian 
males (Kumar & Anderson, 2002). Figure 2 (page 11) provides context to the relationship 
of incidence over time. Animal and in vitro studies have also shown that there is 
significant anticancer activity from SDPs such as genistein and daidzein and that these 
isoflavones may be responsible for the lower incidence of CaP and another condition 
BPH observed among Asian males (CDC, 2010).  
There is also concern that estrogens that were once effective in treating CaP, 
might also be contributory to the development and progression of the disease (Bonkhoff 
& Berges, 2009). Importantly, while this form of therapy appeared to be effective against 
androgen-dependent disease, the potential risk of been associated with malignancy is 
certainly disconcerting (Bosland, 2005). According to (Bosland, 2005) many theories 
have explained this association including evidence of various genetic polymorphism in 
particular codon regions of the ER-α gene that either increases the risk or development of 
CaP. While ER-α has demonstrated this association of CaP development ER-β has 
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demonstrated tumor suppression activity (Bosland, 2005; Giton, de la Taille, Allory, et 
al., 2008). Age as indicated earlier is a significant predisposing factor for CaP. CaP 
appears to be most likely initiated in gland cells and is referred to as adenocarcinomas 
(ACS, 2012). These are the cells that are responsible for the production of the fluid that 
improves the environmental conditions for sperm cells (ACS, 2012). Reports indicate that 
CaPs can experience either slow or rapid growth, and evidence exists of the cancerous 
tumors in older males but mortality been attributed to another disease condition (ACS, 
2012).  
The development of CaP can also be attributed to PIN lesions considered a 
precancerous event and can affect males even in the early decades of life (ACS, 2012; 
Weihua, Warner, & Gustafsson, 2002). Microscopic analysis of biopsied PIN cells and 
determination of the level of their abnormality can be helpful in determining the chances 
of developing CaP (ACS, 2012). There is also a greater chance of CaP occurring when a 
high grade abnormality is assessed during PIN analysis (ACS, 2012). The presence of 
high grade PIN on biopsy also reflects an increased possibility of (20% - 30%) greater 
association with CaP development, and that there are cancerous lesions in other parts of 
the body (ACS, 2012). Other important findings that may be indicated through the biopsy 
process include atypical small acinar proliferation (ASAP) and proliferative 
inflammatory atrophy (PIA) (ACS, 2012). While there is some uncertainty regarding PIA, 
it is still thought of as a precursory event, while ASAP appears to indicate a need for 
follow-up biopsy (ACS, 2012). This seem even more compelling when evidence indicate 
  
42 
the presence of ER-β receptors in normal, hyperplasic and prostate tumor cells, but a 
decreased expression in CaP (Weihua, Warner, & Gustafsson, 2002).  
Prostatic Specific Antigen 
PSA is a protein and falls in the group of serine protease, and is produced by 
prostate tumors (Adams, Chen, Newton, Potter, & Lampe, 2011). Prostate tumors have 
the ability to destroy protective barriers and allow PSA to spill into the blood. This allows 
for serum PSA concentration to be employed as a useful tumor marker (Adams, Chen, 
Newton, Potter, & Lampe, 2011). However, while the concentration of serum PSA 
appears to be proportional to the tumor volume, it is also not always elevated during CaP 
and other situations such as BPH, inflammation and other prostate conditions are 
responsible (Adams, Chen, Newton, Potter, & Lampe, 2011). With increased use of PSA 
as the screening method, there has been the detection of several asymptomatic cases 
among tested populations, which could certainly account for a higher described western 
incidence (Kumar & Anderson, 2002; Bonkhoff & Berges, 2009).  
Consequently, the lack of available testing in some populations might also 
account for undiagnosed cases which could increase the present number. Prevention 
strategies might certainly be the model responsible for reducing the high incidence in 
Western countries, and inclusion of dietary SDPs appears a potentially viable option. This 
research aims to identify through meta-analysis of the data from selected randomized 
controlled trials the dynamics that is evident through analysis and determination of the 
ES of SDPs intervention. This thought is certainly shared by several investigators 
(Landstrom et al., 1998; Mentor-Marcell, Lamartiniere, Eltoun, Greenberg, & Elgavish, 
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2001; Morrissey et al., 2004), in reference to the influence of genistein to decrease tumor 
cells in mice models. Inducing apoptosis in vitro by the SDP resveratrol in selected 
prostate carcinoma cell lines also demonstrated evidence of SDPs on prostate 
adenocarcinoma cell growth (Mentor-Marcell Lamartiniere, Eltoun, Greenberg, & 
Elgavish, 2001). The true effect of SDPs will therefore be unearthed from this intensive 
research process. The prostate gland located at the neck of the male urethra and bladder. 
It is approximately the size of a walnut in younger adults but can be larger in older males 
(ACS, 2012). Figure 4 below shows a healthy prostate with a walnut representation of its 
normal size. Tumors and other infections of the prostate result in an enlarged prostate. 
There is a variation in the size of the prostate and it is usually larger as the man ages.  
 
Figure 4. Healthy Prostate, Nearby Organs and Internal Structures. Source: The Prostate, 
National Cancer Institute, 2012.  
 
In Figure 5 a representation of the prostate gland affected with a developed tumor 
demonstrates the resulting enlargement. The enlarged prostate gland results in secondary 
health issues as it causes constriction of the urethra. Constriction of the urethra is 
associated with problem urinating and other medical issues.  
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Figure 5. Prostate Gland with Identifiable Cancerous Tumor. Source: What is prostate 
cancer? ACS, 2012.  
In some contexts, it is considered both muscular and glandular with ducts that 
open into the prostatic urethra and consist of a central and two adjacent lobes (NCI, 
2012). The prostate gland enlarges with age and this can result in constriction of the 
urethra and subsequent difficulty in the passage of urine (NCI, 2012). The processes that 
encourage growth, differentiation, and functionality of the prostate gland while largely 
dependent on the male hormone androgens, relies in some significant context to the 
action presence of estrogens (Harkonen & Makela, 2004). The enzyme 5-alpha-reductase 
acts on the male hormone testosterone an androgen produced in the testicles converting it 
to dihydrotestosterone (DHT) which subsequently influences growth of the prostate 
(ACS, 2012). The presence of male hormones during the adult life allows the prostate to 
maintain its size (ACS, 2012), but several factors can influence changes that result in 
unfavorable health conditions. Problems involving the prostate appear to begin during 
later decades in life, although earlier problems can affect passage of urine through the 
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urethra (NCI, 2012). Problems that can occur over time include infection (prostatitis), 
benign prostatic hyperplasia (BPH) and CaP (ACS, 2012; NCI, 2010).  
Screening Methods 
CaP screening methods have afforded some amount of earlier opportunity for 
active surveillance and early treatment. However, several concerns have arisen from the 
use of the PSA test which is employed for many years as a major determinant for 
initiating further screening, determining response to various therapies and to predict the 
outcome from treatment. The PSA screening also takes into account the importance of 
values as they relate to percent- free PSA, PSA velocity, PSA density and age-specific 
PSA ranges (ACS, 2012). Complementary modalities including digital rectal examination 
(DRE), prostate ultrasound (transrectal ultrasound), and prostate biopsy have been used 
as independent screening tools (WebMD, 2010). However, these treatments have not 
shown improved survivability and health outcomes (WebMD, 2012). Benefits of earlier 
diagnosis and detection of latent disease achieved through development of improved 
screening techniques (WebMD, 2010). Benefits we can appreciate, although 
accompanied by uncertainties including a high incidence of false positive results (ACS, 
2012). This can result in the unnecessary use of other procedures and high economic 
costs (ACS, 2012).  
PSA Testing and Importance 
Approved by the US Food and Drug Administration (USFDA), the PSA test looks 
at the level of serum PSA. The value ≥ 4ng/ml warrants further testing (NCI, 2012). 
Other testing includes prostate biopsy for tissue analysis or monitoring of PSA velocity 
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(NCI, 2012). These tests reflect changes in PSA levels over specified times (NCI, 2012). 
Elevated PSA levels over time and a positive biopsy might be indicative of CaP (NCI, 
2012). Cells are biopsied, and a Gleason score from 2-10 is assigned following analysis 
(NCI, 2012). Some individuals have shown no increased health benefits from PSA 
analysis (ACS, 2012). There is some controversy about the value of PSA analysis as a 
valuable screening tool (ACS, 2012). Confirmation is evident with an observed mortality 
rate of 3% within a population with a 9% diagnosed incidence rate (ACS, 2012). 
Presently, there is about 2% - 2.5% mortality rate that occurs among the 18% diagnosed 
following PSA screening (ACS, 2012). Mortality rate is within the context of reliability 
regarding PSA values. Increasing PSA might not be significant of CaP, but from 
prostatitis and BPH as indicated earlier. PSA is specific for its association with prostate 
activity and is not itself specific for the association with CaP (Kumar & Anderson, 2002).  
However, a rising PSA following surgical castration and following radiation is 
certainly cause for concern and can be extremely problematic (Vaishamapayan et al., 
2007). Values that are provided through this screening method are therefore, indicative of 
the possible risk of CaP with that risk increasing to ≥ 90% when the PSA level is > 
20ng/ml if the considered level of 2.5ng/ml is considered normal for males between the 
ages of 40 – 49 years old (Kumar & Anderson, 2002). Employing the digital rectal 
examination (DRE) is another screening method that can detect abnormality of the 
prostate gland (ACS, 2012). Tissue biopsy and microscopic analysis of cells is to confirm 
the presence of cancer, and to determine the course of action regarding treatment or 
surveillance (ACS, 2012). Screen due to factors such as age, ethnicity and genetics. 
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Staging provides a good indication of how far the disease has spread following screening 
assessment. The method most commonly employed by clinicians is the elaborate TNM 
classification approved by the American Joint Committee on Cancer (AJCC) which 
assesses the disease centered on the progression of the primary tumor (T), any evidence 
of spread to nearby lymph nodes (N), and evidence of distant metastasis (M) (ACS, 
2012).  
Tumor Grading 
 An important part of diagnosing CaP is the staging process. Information on 
staging comes from an understanding of the disease process. The disease process is 
defined by a system that provides assessment based on the tumor containment or spread 
to other tissues (ACS, 2012, NCI, 2012). Tumor spread and containment are important in 
determining treatment options and other factors such as response to therapy and 
subsequent outcome (ACS, 2012). Grading of tumors is an important part of the 
therapeutic process. Grading helps to define the disease state and provides important 
information on the present status of the disease (ACS, 2012). Both Gleason grade and 
tumor node metastasis (TNM) staging are valuable screening methods, that are associated 
with CaP diagnosis and are available to guide treatment modalities and the potential for 
disease progression or containment (ACS, 2012). They are also extremely focused, 
directed and elaborate scientifically based assessment of the disease process, and is 
therefore invaluable in any therapeutic decision and follow-up care or employed curative 
strategies. Below is the ACS (2012) outline of the application of the Gleason grade, Stage 
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and Score in defining what approaches including chemotherapy, surgery, hormone  
therapy and others might be best suitable for intervention and follow-up strategies. 
Gleason Grading 
 Important to the understanding of tumors is what is considered the ‘Gleason 
Grade’. The ‘Gleason’ grading system classifies tumors based on a staging scale of 1 – 5. 
This staging scale is an indication of the disease at the time of diagnosis (ACS, 2012). 
Grade 1 tumors have cells with the appearance of normal prostate cells (ACS, 2012). 
Cells considered grade 5 on the tumor grading scale are abnormal and poorly 
differentiated (ACS, 2012). These cells have now infiltrated the prostate and are 
observable throughout that gland (ACS, 2012). Cells categorized between grades 2 – 4, 
demonstrate varying increasing ranges of infiltration of tumor cells within prostate tissue 
(ACS, 2012).  
Important to understanding the state of the prostate tumor is through the Gleason 
score. Gleason score is a complementary tool within the assessment process. Most CaP 
tumors have mixed cell types with different tumor grades, and the Gleason score is an 
additional assessment criteria (ACS, 2012). The Gleason score provides a better rational 
analysis of the state of the tumor (ACS, 2012). Tumors are assigned two numbers which 
helps to identify the designated dominant and minor tumors (ACS, 2012). Addition of the 
numbers assigned to each tumor grade then provides a better assessment and subsequent 
description of the present tumor through this assigned score (ACS, 2012). Therefore, a 
dominant grade 2 tumor and a minor tumor grade 4 would classify as six on the Gleason 
scoring scale (ACS, 2012). Appreciation of the value of the Gleason score comes with the 
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understanding that scores range from 2 – 10 with a higher value representing tumors that 
have a greater differentiation from normal prostate cells and those that are likely to be 
aggressive in their ability to spread (ACS, 2012).  
The preceding discussion, therefore represents a generalized outlook that a 
Gleason score between 2 – 4 or Grade 1 cancer is the representation of cancer that can be 
considered low grade and consists of cells that are highly differentiated (ACS, 2012; 
NCI, 2012). A Gleason score between 5-7 or grade 2 cancer, represents a cancer that 
consist of cells that are moderately differentiated (ACS, 2012; NCI, 2012). A score of 8-
10 on the Gleason scale, represents a Grade 3 cancer, consist of poorly differentiated 
cells. The grade 3 tumor represents tumors considered high grade (ACS, 2012; NCI, 
2012). While poorly differentiated cells are possibly a definitive representation of high 
grade tumor that needs aggressive treatment the problem concerned those cells which are 
moderately differentiated as there appears to be no significant model of determining the 
progression of these cells, and this is apparently a significant volume of the cancer grades 
identified during diagnosis (ACS, 2012; NCI, 2012).  
While grading provides invaluable information on proliferation of tumor cells 
within the prostate tissue, another important tool within the broad diagnostic process, is 
that considered staging. Here, is another tool which while complex in its assessment 
provides even greater capability and context to the diagnosis process, in its ability to 
providing a more thorough understanding of the disease in relation to the spreading of the 
cancer outside of the defined gland (ACS, 2012). There are two recognized staging 
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methods used during CaP staging. The one employed most during CaP staging which and 
approved by the AJCC (ACS, 2012) is described. .  
The American Joint Committee on Cancer System  
A staging system is a standard way for the cancer care team to describe how far a 
cancer has spread (ACS, 2012). The most widely used staging system for CaP is the 
American Joint Committee on Cancer (AJCC) TNM system (ACS, 2012). The ACS 
document indicates that there are five important areas regarding the TNM system (ACS, 
2012). These are important determining factors for staging of the disease and certainly 
could be important for influencing and employed treatment strategy. In this AJCC staging 
system there are several important concerns. The concerns include the degree of the 
primary tumor (T category), the presence or absence of tumor metastasizing and if lymph 
nodes (N category) that are near the tumor are affected (ACS, 2012). These are the 
components of the TNM system. The PSA level at diagnosis, the Gleason score following 
surgery or when biopsied are also important in the diagnostic process (ACS, 2012).  
Pathophysiology of CaP 
While the development of CaP in humans is still defined by the difficulty in 
establishing its true etiology, evidence suggests some similarity between the disease and 
that described in male canine (Waters et al., 1998). According to this model, several 
defining similarities exist between both species including the development of PINs, the 
late onset of the disease, and the variation exhibited morphologically and genetically in 
observed prostatic lesions (Waters et al., 1998). The canine model certainly appears to 
explain several components of the disease. Among areas that are defined through this 
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similarity and support the use of the canine model are progression of the disease, ability 
to define predisposing factors and testing of therapeutic agents (Waters et al., 1998). The 
issue of PIN progression to tumor growth and subsequently metastasis of the disease is 
therefore important (Waters et al., 1998).  
However, while the above is indicative of the positive value of other mammals in 
understanding CaP tumor, (Maini et al., 1997) there is an indication of limitations 
including reduced spontaneity, and the fact that canines are more difficult to manipulate 
genetically. Employment in this type of research could also be potentially expensive. 
With problem depending on mammalian models to understand CaP development, using 
transgenic mice have been valuable. The transgenic mice allows for understanding the 
importance of neuroendocrine cells in CaP development. Neuroendocrine cells are rare 
within the prostate. However, they contribute significantly to the development of very 
aggressive prostate adenocarcinoma that is also observed in humans (di Sant’ Agnese, 
1998). The transgenic mice model is also of tremendous value in attempting to 
understand the issue of CaP development without androgen stimulation. , although 
preceded by the presence of PIN and a rapidly metastasizing tumor (Garabedian et al., 
1998).  
CaP is still a very difficult disease to understand and transgenic mice model 
provides a valuable opportunity to study the neuroendocrine disease development and the 
complex role of neuroendocrine cell type in disease etiology (Garabedian et al., 1998). 
Transgenic mouse models’ do provide some insight into possible development of CaP, 
but the value xenographs, representative of human CaP lines such as LNCaP and CWR-
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22 have in some context seen some difficulty because of species differences (Stearns et 
al., 1988). However, their use has provided important context to the issue of 
chemoprevention and drug development (Stearns et al., 1998). What appears to be of 
interest regarding the use of mammalian models to understand CaP development and 
progression is the combination of many interacting factors and ones that illustrate a 
complex disease. These complex associations are also likely to be integral in not only 
development of the disease but the progression, metastasis and the complex nature of 
recurrence.  
Biology of the Prostate 
The prostate gland is about walnut size and located at the neck of the male’s 
urethra and bladder. The gland is both muscular and glandular and has ducts that opens 
into the prostatic urethra; it has a central, right, and left side adjacent lobe (ACS, 2012). 
While several important functions are attributable to the prostate gland, with age there are 
important changes that can lead to conditions including benign prostatic hyperplasia 
(BPH) and CaP (ACS, 2012). With age increase, the prostate undergoes growth changes 
including a doubling in size during puberty (ACS, 2012). However, while the prostate 
continues to grow throughout the lifespan of men, enlargement can occur and result in 
problems, especially after the age of 60 (ACS, 2012). In fact, greater than 50% of BPH 
cases occur after that age and increasing age poses a greater risk (ACS, 2012). BPH is 
associated with thickened bladder wall, irritation, frequent urination, and urgency even 
when there is only a small amount of urine. Although BPH is a natural part of the aging 
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process, a decrease in the ratio of testosterone to estrogen hormonal levels can result in 
increased prostate growth (ACS, 2012). Estrogen is predominantly a female hormone.   
A second theory implicates the continued production of dihydrotestosterone 
(DHT) a substance derived from testosterone and which controls prostate cell growth 
(ACS, 2012). The continued production of DHT and its storage in the prostate, even with 
the reduced production of an age decreasing testosterone, results in continued cellular 
growth (ACS, 2012). A third theory emphasizes the concept of cellular instructions from 
earlier initiated instructions for cellular growth. Cells that have early growth initiated 
instructions, could themselves resume growth or provide growth instructions to other 
cells. Instructions could involve greater sensitivity to hormones that could then influence 
growth (NKUDIC, 2010). This theoretical model could explain since cellular activity is 
continually under biological influence. The DPIM also addresses chemoprevention under 
these conditions and therefore provides the best model for this study.  
Staging 
Staging is an important part of diagnosis and the therapeutic process. There is also 
a greater understanding of the disease and certainly an opportunity for discourse between 
health care professional and individual. There are two staging methods associated with 
CaP diagnosis (ACS, 2012). The clinical stage provides an opportunity for the physician 
to have the best estimation of the present disease status (ACS, 2012). Several areas 
including findings from laboratory tests, prostate biopsy, and physical examination 
including the DRE, and imaging studies are very valuable (ACS, 2012). The second stage 
or pathologic stage, when analysis of extracted tissue is completed (ACS, 2012). Staging 
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types can result in differences in assessing cancers for staging since tissue removal and 
assessment could indicate a change in location of cancer cells (ACS, 2012). Staging also 
provides a realistic assessment of the cancer, as it provides a more detailed assessment of 
the disease process (ACS, 2012). Pathologic staging is dependent on analysis of the 
removed tissue, then it might be appreciated as advantageous in employing radical 
prostatectomy than the modalities of watchful waiting (expectant management) or 
radiation therapy’ (ACS, 2012).  
Staging employs various categorical assessments in determination of CaP disease. 
However, the category denoted as T1 is not among those used when defining pathologic 
staging of the disease (ACS, 2012). The staging categories presented provides a brief 
description of this process (ACS, 2012). There are four (4) categories for clinically 
describing the local extent of a prostate tumor, ranging from T1 to T4 with most 
consisting of subcategories (ACS, 2012). The N categories describe whether the cancer 
has spread to nearby (regional) lymph nodes (ACS, 2012).The M categories describe 
whether the cancer has spread to distant parts of the body with the most common sites of 
CaP spread been bones and distant lymph nodes (ACS, 2012). The lungs and liver are 
other tissues, which CaP can affect (ACS, 2012).  
Estradiol 
The secretion of E2 is from ovaries in females. E2 is an estrogen hormone. 
However, males secrete smaller quantities between 5-40 pg/ml. Studies have also shown 
the effectiveness of E2 for cancer chemoprevention.  
 
  
55 
Stage Grouping 
Stage grouping follows a determination of the T, N, and M categories (ACS, 
2012). Stage grouping is the cumulative assessment of CaP staging, Gleason scoring and 
prostate-specific antigen (PSA) concentration (ACS, 2012). If Gleason, score or PSA 
concentration is absent then staging relies on the T, N, and M categories (ACS, 2012; 
NCI, 2012). The use of Roman numerals provides an indication of how advanced the 
when diagnosed. Cancers that are least advanced is represented by the numeral I and IV 
and provides a representation of the most advanced cancer (ACS, 2012). This 
representation through numeric values help to determine what options are available for 
treatment and the prognosis for survival outlook (ACS, 2012). A second staging model 
the Whitmore–Jewett system has staging algorithm based on A, B, C and D staging. Less 
use is made of the Jewett system in the clinical setting (ACS, 2012). However, if used 
during the screening process, effort should be to provide comparative assessment based 
on the more widely employed TNM system (ACS, 2012).  
Dual Prevention Integrated Model 
The study initially considered the putative multistep cellular biochemical pathway 
model by Giovanni (1999). While this theoretical concept defines a biochemical pathway 
to CaP etiology and provides some constructs for the theoretical basis of this study, it 
does not address the primary and secondary basis for chemoprevention within the public 
health framework. The DPIM (Michelin & Gutierrez, 2013) presented in Chapter 1 is an 
original framework addressing the conceptualized primary and secondary strategies 
needed to address the process of CaP and other cancers. The DPIM is structured on the 
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premise that dietary intake levels of SDPs, in particular genistein and daidzein, are 
associated with the prevention of cellular damage responsible for the lower incidence of 
CaP observed among males in Asian countries. Theoretical models proposed in the 
literature have identified mitigating factors that result in cellular biological activities 
leading to development and progression of CaP. The goal of these models and of this 
research is the elucidation of factors which if manipulated could reverse or prevent CaP 
disease by addition of specialized isoflavones within dietary or medicinal contexts able to 
avert progressive development of prostate tumors. Among the mitigating factors, age, 
inflammation, change in hormonal status and genetic mutations are key. While several 
studies have provided scientific support for the events describing such association at the 
cellular level, a primary prevention approach has not been taken into consideration. 
Therefore, in addition to the conceptual approach, meta-analysis of the relevant literature 
and determination of the true ES of SDP intervention on individuals with various stage, 
grade or type of CaP remains an important gap in the literature. 
The model defined by Michelin and Gutierrez (2013) guides the conceptualization 
of this study providing a framework for initiating dietary SDPs as a chemoprevention 
strategy. The early evidence of damage to the normal prostate tissue resulting in genetic 
mutation and cellular damage (Giovannucci, 1999) provides an early opportunity for this 
chemopreventive access. In contrast to the development of neoplasia as decribed in the 
model by Giovanucci (1999), the DPIM focuses on preemptive chemoprevention through 
SDPs to prevent and reduce early prostate tissue damage (Michelin & Gutierrez, 2013). 
Averting further tissue damage by implementing DPIM strategies is the primary 
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prevention function. Other therapies including Androgen Deprivation Therapy (ADT) 
and other chemotherapeutic agents might provide some positive response (Giovannucci, 
1999). SDPs can also function where ADT is required and have shown to be successful. 
The proposed study also addresses the problem of recurrence and identification of 
potential failure for any successful therapeutic intervention. Through the DPIM the study 
demonstrates the opportunity for SDP chemoprevention. There is also the potential for 
immunotherapeutic exploration. The model certainly accounts for that prospect through 
the indication of antibody intervention. Other models include the role of oxidative stress 
(Thapa & Ghosh, 2006) and environmental factors in the disease process. The context of 
the seminal role of the proposed study allows for greater application of the Michelin and 
Gutierrez (2013) model at it sought to determine the ES of SDP intervention and the 
potential for chemopreventive treatment. 
Additional research has also demonstrated the value of antioxidant enzymes (Jung 
et al., 1996) during in vitro antitumor analysis. Genistein is also a valuable inhibitor of 
CaP cell proliferation through activity that affects the EGFR-Akt/p70S6K pathway and 
by down regulating important androgen receptors (Oh, et al., 2010). Genistein’s use 
supports the hypothesis that values plant derived compounds as effective biological 
antitumor agents. This evidence is provided through several in vitro studies that have 
implied an inverse activity in endocrine-resistant tumor cells (Lian et al., 2003), such as 
apoptosis through the activity of a flavonoid derivative (Chan et al., 2000; Patra et al., 
2011), and down regulation of PSA (Han et al., 2007). Hormone refractive CaP following 
radical prostatectomy (surgical castration) poses tremendous challenges even with the 
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best medical therapies and is associated with poor survival outcomes (Hess-Wilson & 
Knudsen, 2006). Meta-analysis of selected randomized controlled trials involving CaP 
patients between 50 and 70 years old allowed better understand of the defining principles 
that allow SDPs such as genistein and daidzein to valuable for chemoprevention. Even 
within the context, that CaP could also be hormone driven through the intricate 
associations of estrogens and testosterone (Maskarinec et al., 2006).  
Difficulty in treating hormone refractory CaP (Celhay et al., 2010) has resulted in 
the employment of combinations of presently used drugs such as paclitaxel (taxol) (Ping, 
Hour, Ling, & Yu, 2008).  Other combinations include employing several plant based 
compounds including antioxidants, epigallocatechin gallate and genistein (Ping, Hour, 
Ling, & Yu, 2008). Studies employing TRAMP mice at different stages of the 
developmental process throughout life showed the latter establishing an approximate 50% 
reduction in the development of poorly differentiated prostate tumors when compared to 
controls (Wang, Eltoum, & Lamartiniere, 2007). These studies are supportive of evidence 
from epidemiological data implicating the presence of soy in Asian diets as the rationale 
for this lower CaP incidence.  
Estrogens and Cancer Etiology 
There is valuable information that provides support to the role of estrogen in 
cancer etiology (Ganry, 2005). The inverse relationship between estrogens and cancers is 
continually reported (Kumar et al., 2011). However, greater role for SDPs is necessary 
due to the increase in adverse event become associated with exposure to animal derived 
estrogens (Colli & Colli, 2005). Plant derived SDPs include genistein and daidzein two 
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major phytochemicals, which are the focus of this study. They have become associated 
with chemoprotection and the beneficial association in decreasing CaP incidence seen in 
some populations (Dalais et al., 2004). The ES of such biochemical activity is the focus 
of this intensive discourse. It will provide a better evaluation of the true relationship 
between the effect of SDPs and response in PSA and E2 levels. These are valuable 
markers for cancer progression or therapeutic response. Estrogen is important to many 
biological events including the early initiation of prostate development; however, as 
indicated there is also some supportive evidence of its role in CaP development (Ganry, 
2005).  
However, this premise is open to some amount of criticism since there is also 
evidence of CaP recurrence following surgical castration, and therapy employed to 
disrupt hormonal activity in the prostate gland (Feldman & Feldman, 2001; Hess-Wilson 
& Knudsen, 2006; Leewansangtong & Soontrapa, 1999). What is apparent is that the 
models by (Giovannucci, 1999) and (Thapa & Ghosh, 2004), appear to be significantly 
opposite in the approach to describing CaP development. The model by (Thapa & Ghosh, 
2004) links the metabolism of androgen to the development of CaP (Friedman, 2005). 
Certainly, there is a close association between hormonal influence and early initiation of 
prostate development. Subsequently, the continuing influence of hormones can be a 
determining factor in the early development of the disease. Ross et al., (1998) implies, the 
evidence expounded regarding such link, might lack any realistic context. This argument 
certainly demonstrates a need for further understanding CaP development. Defining how 
such biological activity through isoflavones such as genistein can influence disease 
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prevention or developmental delay is also prudent. A second model associates androgen 
administration to the development of the disease (Prehn, 1999). Suggestions regarding 
androgens as an important initiator for CaP development come from earlier evidence 
regarding a developmental association between the prostate gland and that hormone 
(Ross et al., 1998). However, questions were again raised regarding the issue of hormone 
independent CaP, which has allowed for hypothesizing a broader developmental 
construct for the disease (Ross et al., 1998). Subsequently, a more recent genetically 
associated model the Estradiol-Dihydrotestosterone (E-D) is now been suggested (Ross et 
al., 1998). The E-D model is defined through a complex of interactions of specific genes, 
and provides value to ethnic factors that has been proposed (Ross et al., 1998). This study 
examines the context of ES based on these factors, since hormonal response is associated 
with the basis of SDP activity. Here, the levels of PSA and E2 are among the markers 
that allow for examination of such posited association.  
Analysis of SDP intervention data provides some context to the value of soy-
based diets and the role of particular isoflavones such as genistein and daidzein in disease 
prevention/treatment will be central to this research process. The estrogenic activity of 
SDPs and the influence hormones such as E2 during the therapy was determined from the 
analysis process. Research has indicated that soy derived SDPs such as those referenced 
throughout this discourse and especially genistein possess strong antioxidant properties 
important in the chemoprotective ability. The need to understand the true effect of SDPs 
on CaP is also within the context of the presentation of some results from studies 
categorized as inconclusive following data analysis (Nakamura et al., 2011). In a study 
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employing mice, there is reference made to the progression of tumors to secondary 
organs and associated with lymph node infiltration (Nakamura, et al., 2011; Napora, et 
al., 2010). However, (Swami, et al., 2005) present results which are the contrary to those 
previously reported and mention the inhibitory effect of the isoflavone genistein during in 
vitro analysis on DU 145 human CaP cells.  
Estradiol and PSA 
Numerous studies allude to the changes that occur over time in relation to the 
influence of both the disease state and the intended intervention on PSA and E2 levels in 
the prostate gland. The reference range for E2 among adult males is 10-40 pg/ml (Adams, 
Chen, Newton, Potter, & Lampe, 2004); Kumar et al. 2007); Miyanaga et al., 2012; 
Schroeder et al., 2005; & White et al., 2010). There appears to be a certain amount of E2 
hormone produced in males. Evidence points to a decrease in E2 during the CaP disease 
process. Presence of SDPs appears to have a positive relationship with E2 levels in the 
prostate gland. Therefore, intake of SDPs will have a direct increase in estriadol and 
decrease disease progression. However, the inverse relationship occurs between SDPs 
and levels of PSA. PSA is the marker employed to assess either tumor presence, response 
to therapy, and in some context the evidence of any health outcome. The literature is also 
marked with uncertainties, a dilemma that still confronts those diagnosed or treated for 
CaP. Numerous in vitro studies have demonstrated a positive chemoprotective role from 
SDPs on different tumor cell lines (White et al., 2004), but conflicting evidence is 
presented when human trials have been conducted (Sharma et al., 2009). Some studies 
reflect positive associations, but the strength of those associations has not undergone 
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rigorous examination. The magnitude and direction of the association was determined 
through this dissertation.  
Evidence and Interpretation of CaP Development and Treatment 
Both evidence and interpretation proposed for the initiation, progression and 
failure of ADT and other therapies differ. While most theoretical models support the role 
of several factors including age, genetic mutation, exposure to environmental toxicants 
and nutrition, as important, the central dogma reflected through those theories seems to 
focus on the influence of Reactive Oxygen Species (ROS). Different explanations 
regarding tumor initiation and the subsequent events that are responsible for hormonal 
and PSA fluctuations have been provided as well. Diet as implied, is among the factors 
that have an influence on the development and progression of CaP. Such concern is 
shared by (Marks et al., 2004) when looking at the differences in prostate tissues in males 
living in both westernized and an Asian locale, but from a similar ethnic background. 
While the conclusion from this study supports the importance of environmental factors in 
predisposing to CaP development, those factors such as lower E2 and urinary soy 
metabolites levels provided important correlational context. In this study, both were in 
Japanese American males than Non Japanese males, which could be indicative of lower 
consumption of soy-based products. Loss or absence of phytoprotection attributable to 
SDPs could certainly be an integral factor in allowing disease progression.  
In the theoretical model proposed by Khandrika, Kumar, Khoul, Maroni & Koul, 
(2009) the damaging implications of ROS on cellular structures such as nrf2 and 
disruption of specialized nrf2-nRE axis appear more pronounced during a lower 
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antioxidant environment. Progression and the subsequent detriments of cellular damage 
from increased ROS also appear to target cells that have a greater antioxidant capacity 
therefore, exposed to greater damage (Khandrika, Kumar, Khoul, Maroni & Koul, 2009). 
Similar opportunity for antioxidant damages were observed in an earlier model (Valko, 
Rhodes, Monkol, Izakovic, & Mazur, 2006). Here, there is cellular damage resulting from 
ROS, which leads to DNA damages. This subsequently progresses to preneoplastic 
conditions and could potentially progress irreversibly, leading to a cancerous state 
(Valko, Rhodes, Monkol, Izakovic, & Mazur, 2006). This model certainly accounts for 
similar factors such as oxidants and carcinogens that places stress on the homeostatic 
condition, and subsequently leads to the precancerous state with further potential for the 
development of cancerous lesions (Khandrika, Kumar, Khoul, Maroni & Koul, 2009). It 
appears that with the initiation of antioxidant intervention, through SDP inclusion, that 
cellular damage could be delayed, prevented or reversed (Khandrika, Kumar, Khoul, 
Maroni & Koul, 2009). Support for this is presented in the research by Borek (2005) 
when there is mention of antioxidants as potentially useful for preventing certain cancers 
that are known to be hormonally regulated. The evidence supports that among these are 
CaP, breast and endometrial cancer. The results from this study could be important in 
defining how other cancers are approached within the context of prevention, treatment 
and management of the disease.  
This is important especially since breast cancer among females have a 10-20% 
recurrence following initial treatment, which is associated with a five-year cancer-free 
status (Borek, 2005). Also important is the recurrence associated with CaP which was 
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mentioned earlier in this discussion and is considered to be between 18 – 24 months 
(Reference). While antioxidants such as vitamin E and C are employed to prevent 
recurrence in many females, a similar trend in use has also been seen in males diagnosed 
with CaP. Antioxidant activity, which has become associated with SDPs might certainly 
play an important role in the lower CaP incidence. While these models appear to 
introduce the variable of SDP within the disease process, post-cellular destruction by 
factors responsible for initiating CaP development is still evident.  
Another important view on possible prevention of CaP development, is posited 
through the mediation of topoisomerase II activity which is an important enzyme in DNA 
synthesis (Patra et al., 2011). Here, topoisomerase II∞ is seen as the predominant enzyme 
in cells that are proliferating and is therefore significantly expressed in tumor cells (Patra 
et al., 2011; Hsinang et al., 1988; Heck & Barnshaw, 1986). 
Literature on Methodology of Studies on SDP and CaP 
Meta-analysis was the methodology employed for this study as it allowed for 
greater understanding of the ES response of SDP treatment on the populations assessed 
through different studies selected for this research. An appreciation of this study certainly 
provides the opportunity to conduct what can also be considered ‘quantitative syntheses’, 
of the data obtained from primary research employing statistical methodology (DeCoster, 
2004). In reference to thoughts shared by (Marsh, Johnson & Carey, 2001), employing 
meta-analysis will also provide a more in depth understanding and explanation of those 
integral associations between SDPs and the initiating biochemical, environmental and 
personal factors that result in disease development and progression. This in depth 
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appreciation of the value of meta-analysis allows for employing it as a tool for statistical 
evaluation of interventions and the subsequent success that can be attributed to their 
implementation (Marsh, Johnson & Carey, 2001).  
The larger population size made possibly by pooling several studies and analyzed 
through meta-analysis provides the probability for even greater reliability and validity of 
the findings. The analysis therefore provides more value to the intervention process and 
improves its reliability and validity. In medicine meta-analysis seeks to assess 
intervention in terms of ‘treatment effect’, and this can sometimes be referenced through 
statistical measures such as odds ratio (OR), risk ratio (RR), or risk difference (RD) 
(CMA, 2006). In relation to studies focused on the social sciences, meta-analysis 
employs the term ‘effect size’ in reference to ‘standardized mean differences and 
correlations’ (CMA, 2006). However, both references can be employed during meta-
analysis application and is reflected throughout this study. However, while the use of 
some statistical tools including Cohen’s d, multiple regression and ANOVA can be used 
to generate “treatment effect or [ES]” data. The availability of a professionally designed 
comprehensive meta-analysis software, allows for even greater specificity, validity and 
improved reliability of the computed data. Such professionally designed analytical 
software allows access to all statistical tools in an individual package and employed to 
generate more statistical reproducible results. While two forms of meta-analyses are 
available, this study will employ the method designed to analyze quantitative research 
literature. This study as implied will be a meta-analysis of the effect of soy derived SDP 
compounds on PSA and E2 levels before and during intervention. How such an 
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intervention can be quantified as a consequence of the “Effect size or Treatment size” 
observations will be studied (CMA, 2006). This reference is pertinent since there are both 
treatment and control groups involved in these studies and the resulting evidence is 
generated from a contrast between sometimes quite differing interventions (CMA, 2006). 
While some studies that seek to understand an effect but has no evidence of treatment 
intervention, this would be defined as a more thorough “effect size” association (CMA, 
2006). This study also exemplifies the dual role of different statistical measures (CMA, 
2006). Using these tools as part of the methodology process, will allow for closer scrutiny 
of data output, and the opportunity to understand various context of that data as it relates 
to the size of the effect when multiple regression and Cohen’s d are employed for 
analysis.  
Summary and Transition 
This chapter has provided information regarding different aspect of the present 
state of the research regarding CaP and particularly to that relating to the issue of SDPs, 
as prudent chemopreventive or therapeutic agents. Other models suggest, there are many 
factors that contribute to the development and progression of CaP. Significantly, while 
there is some indication of intervention following cellular damage and possibly where 
this might be irreversible, none of the models appear to present earlier isoflavone 
intervention, or an ES response to therapy employing these plant derived compounds. 
There is similarly a lack of definitive evidence in the context of SDP intervention, 
through research, that also provides a defining relationship between the effect of SDPs 
and PSA and E2 levels. Therefore, while the literature points to a decrease in PSA and E2 
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in pre-cancerous situations, there still needs to be statistically defining correlational 
assessment since those values might not singularly reflect disease state. Positive 
treatment response or therapeutic outcomes might also be absent. Meta-analysis was done 
using selected randomized-controlled trials will be able to provide greater appreciation 
for the value of SDPs in managing many aspects of CaP development. The next chapter 
will therefore provide a through outline of the process to be employed in conducting this 
research. It will outline the value of meta-analysis within public health research and 
especially in understanding issues relating to disease intervention strategies and response 
to those interventions.  
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Chapter 3: Research Method 
Introduction 
The purpose of this study was to determine the ES, magnitude, and direction of 
PSA and E2 serum levels following chemoprevention using the SDPs genistein and 
daidzein. The response of serum levels of PSA and E2 are important markers for 
therapeutic response and prognosis for different types of CaP disease outcome. Analysis 
focusing on this cohort of US men is deficient. The REM answered five major theoretical 
questions relating to the intake of dietary SDPs and subsequently the response of serum 
SDP, PSA, and E2 levels. Odds ratio (OR) employing the 2x2 contingency table was 
used to determine the effect of SDP the independent variable on dependent variables 
serum SDP, PSA and E2 levels. Meta-analysis was used to determine the cumulative ES 
and magnitude and direction of the independent variable on the various dependent 
variables. This chapter describes the research design and approach to determine the 
influence of chemoprevention using dietary SDPs. The effect of the intervention in 
influencing change in serum levels of PSA and E2 was determined. The published 
articles used in this meta-analysis comprised of the instrumentation and materials. The 
data collection process described the initial search strategy and how the literature was 
sorted prior to selection of those that met the study criteria. Finally, the data analyses 
section reviewed the research questions and hypotheses and the use of the REM to assess 
the ES. 
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Research Design and Approach 
Meta-analysis is the approach and design employed in conducting this study. The 
approach follows that used by many researchers including Ma, Qin, Wang, and Katoh 
(2008). It is important to appreciate this as a method which provides an opportunity to 
conduct what can also be considered quantitative syntheses of the data obtained from 
primary research through the employment of a statistical methodology (DeCoster, 2004). 
In reference to thoughts shared by Marsh, Johnson, and Carey (2001), employing meta-
analysis also provided a more in depth understanding and explanation of those integral 
associations between SDPs and the initiating biochemical, environmental, and personal 
factors that result in disease development and progression. The in-depth appreciation for 
the value of meta-analysis allowed it to be employed for reliable statistical evaluation. 
These evaluations include examination of interventions and determining if any reported 
success or failure is attributable to the inclusion or lack of implementation (Marsh, 
Johnson, & Carey, 2001).  
Meta-analysis is beneficial to the research process and demonstrates the ability to 
sythesize systematically the ES findings among several studies (Kraemer, 1983). This 
provided a broader platform on which to evaluate the effects of a particular intervention 
(Kraemer, 1983). The value of meta-analysis to combine several studies therefore 
allowed for the cumulative determination of correlation or association between variables. 
This occurred in this study as treatment and responses were analyzed on the effect seen 
within broader population. Variables were coded and the true effect size of the 
intervention was determined through the indicated analytical applications. Those included 
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OR, Hedges’s g, and the RMD that demonstrated the association between test variables 
and response outcomes. Meta-analysis allowed for analysis of a larger population. This 
analysis provided increased probability of greater reliability and validity to be expressed 
by the meta-analysis findings. In medicine meta-analysis seeks to assess intervention in 
terms of treatment effect. Treatment effect can be acknowledged through statistical 
measures such as odds ratio (OR), risk ratio (RR), or risk difference (RD; CMA, 2006).  
In relation to studies focused on the social sciences, the term effect size, is 
applicable in meta-analysis (CMA, 2006). Another term that is applicable is the 
standardized mean differences and correlations (CMA, 2006). However, both references 
could be employed during meta-analysis application and is reflected throughout this 
study. In addition, while the use of some statistical tools including Cohen’s d, Hedges’ g, 
Odds ratio (OR), multiple regression and ANOVA can be used to generate treatment 
effect size data, through the availability of the professionally designed CMA software, 
allowing for greater specificity of the computed data. Inclusion of all separately indicated 
ES tools provided ready availability and access to all reliable statistical tools.  
While two forms of meta-analyses are available, this study employed that defined 
to analyze quantitative literature research. This study as implied studied the effect of 
SDPs on PSA and E2 levels before and after intervention and assessed its effect relative 
to the effect size or treatment size observed (CMA, 2006). This reference is pertinent 
since there are both treatment and control groups involved in this study and the resulting 
evidence is generated from a contrast between intervention and control/placebo (CMA, 
2006). In studies that sought to understand an effect but with no evidence of treatment 
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intervention, defining those would be done through an “effect size” association. This 
study exemplified the dual role of both statistical measures (CMA, 2006). Using these 
tools as part of the methodology process allowed for closer scrutiny of data output and 
the opportunity to understand various context of that data as it relates to the size of the 
effect when multiple regression and Cohen’s d are utilized within the analysis process.  
Setting and Sample 
The sample for this study was obtained from eight RCT studies, yielding 527 
participants. One advantage of meta-analysis is to provide a larger population on which to 
determine the effect of the intervention, a valuable tool for ES measurement (Wilson, 
2010). Determination of the magnitude and direction of the intervention is an important 
facet of any study (Wilson, 2010). SDPs were the independent variables, and manipulated 
relative to population size, age of participants and the duration of the study. Meta-
analysis use of REM, and Hedges’ g statistic are among those that can mitigate against 
any error or confounding in and between studies. Similarly, the dependent variables, 
which included PSA and E2 serum concentration, considered population size as an 
important factor. Other variables including age, duration and volume of SDPs and other 
study factors that could influence results were controlled through meta-analysis.  
Instrumentation and Materials 
The analytical method followed in designing this study to investigate the dose-
response effect of SDP intervention on PSA and E2 levels is illustrated in Figure 1 
(Chapter 1, page 4). The characterization of the studies followed the pattern outlined 
below. Measures available included study name, study author, length of the treatment 
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(days), number of subjects involved, the type of intervention, cancer status of the 
subjects, age of the subjects, indices employed in generating scores for the DV that were 
assessed (i.e PSA value before and following treatment with either Genistein, Daidzein or 
both Genistein and Daidzein), the score associated with the calculated response (+/-), and 
the outcome experienced following the employed intervention. The weighted mean 
difference of PSA and E2 levels was determined at 95% CI for the treatment initiated in 
each RCT and presented in a tabular format. A forest plot of the differences in PSA and 
E2 values resulting from SDP intervention produced the overall mean and OR of the 
effect of the intervention.  
Variables 
The independent variable in this study consisted of the various quantities of the 
SDPs genistein and daidzein. The dependent variables in this study included dietary and 
serum E2 and PSA levels following treatment employing genistein and daidzein.  
Several tools used in the statistical analyses included the prior indicated ‘effect 
size’ statistics such as OR, CMD, correlation, and Hedges’ g. These are all available in 
the CMA (statistical software) (MetaStat, 2012). They ensure the study’s reliability and 
validity of the resulting data (Campbell, French, & Gendreau, 2009). These instruments 
and materials were associated with data collection and were integral to the meta-analysis 
employed in this study to determine the ES. These determined the association between 
the studied intervention and the experimental groups regarding SDP intake and PSA and 
E2 dose-response.   
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Data Collection and Statistical Analyses 
The data were retrieved from eight published randomized-controlled trials 
(RCTs). These studies had employed both treated and control designed experiments. 
There are two methods of conducting meta-analysis namely (a) fixed and (b) random 
effects models (Borenstein, Hedges, & Rothstein, 2007). In this research, the REM will 
be employed as it appears more suitable for determining relationships sought including 
the important process of ES (Borenstein, Hedges, & Rothstein, 2007). As different RCTs 
have been employed factors such as age and intake duration not accounted for in the 
studies, could result in different ES results (Borenstein, Hedges, & Rothstein, 2007). The 
REM also allows for diminishing the random error that can be present within individual 
studies, through the expansion of the sample size resulting from the use of different 
studies (Borenstein, Hedges, & Rothstein, 2007). In fact, employing the REM in this 
research could seem more prudent since the fixed effect model (FEM) assumes a similar 
ES from all the studies which in fact might certainly not be affirmed and would be 
remedied through use of the REM (Borenstein, Hedges, & Rothstein, 2007). The 
principle therefore in employing the REM was based on the premise that the mean of the 
different effects is a better representation of the true effect of the intended intervention 
(Borenstein, Hedges, & Rothstein, 2007).  
The meta-analysis process consisted of screening several hundred articles looking 
at the effect of SDPs using randomized controlled trials. Studies that employed in vitro 
and other study methods provided reference information. Presented below (Figure 6) is 
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an outline of the research process. The research process included the complete process of 
selecting and eliminating appropriate RCTs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Selection Process of RCTs included in Meta-Analysis. Source: Michelin, 2012.  
Search criteria defined, screening and identification of 
potential articles that might be relevant for this study  
Exclusion of non-RCT articles and those not 
meeting other study criteria 
Selected RCT articles were subjected to further evaluation  
Further selection and exclusion occur to meet 
defining inclusion criteria  
The articles for this meta-analysis were selected from the 
available applicable studies  
The basis for withdrawing any identified RCTs 
prior to the final selection are provided.  
Selection of RCTs that met study’s criteria carried out from 
the available group of studies.  
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Research Questions and Hypotheses 
The ingestion, duration and concentration of SDPs are responsible for the 
associated lower incidence of CaP, and other prostate diseases observed among Asian 
males. Inversely, its decreased intake among males in Western countries appears to be 
associated with a higher incidence of CaP and other prostate diseases. A number of 
questions therefore, need to be answered that may provide some perspective on the 
effects of different independent variables on dependent variables and subsequently on 
disease outcome among males in Wetsern countries. The proposed study seeks to answer 
the following questions:  
Research Question 1: Is there a correlation between dietary SDPs and serum SDP levels? 
Null Hypothesis H1o: There is no correlation between dietary SDP levels and 
serum SDP levels. 
Alternative Hypothesis H1A: There is a correlation between dietary SDP levels 
and serum SDP levels.  
Statistical Plan: IV=Dietary SDPs; DV=Serum SDP; Statistical Test=θi  = μi + ζi   
Research Question 2: Is there a correlation between dietary SDP levels and serum PSA 
levels?  
Null Hypothesis H2o: There is no correlation between dietary SDP levels and 
serum PSA levels. 
Alternative Hypothesis H2A: There is a correlation between dietary SDP levels 
and serum PSA levels.  
Statistical Plan: IV=Dietary SDPs; DV=Serum PSA; Statistical Test=θi  = μi + ζi   
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Research Question 3: Is there a correlation between dietary SDP levels and serum E2 
levels?  
Null Hypothesis H3o: There is no correlation between dietary SDP levels and 
serum E2 levels.  
Alternative Hypothesis H3A: There is a correlation between dietary SDP levels 
and serum E2 levels.  
Statistical Plan: IV=Dietary SDPs; DV=Serum E2;  
Statistical Test=Ti = θi + εi  
Research Question 4: Is there a correlation between serum SDP levels and serum PSA 
levels?   
Null Hypothesis H40: There is no correlation between serum SDP levels and 
serum PSA levels.  
Alternative Hypothesis H4A: There is a correlation between serum SDP levels and 
serum PSA levels.  
Statistical Test: IV=Serum SDPs; DV=Serum PSA;  
Statistical Test= Ti = θi + εi   
Research Question 5: Is there a correlation between serum SDP levels and serum E2 
levels? 
 Null Hypothesis H5A: There is no correlation between serum SDP levels and 
serum E2 levels. 
 Alternative Hypothesis: There is a correlation between serum SDP levels and 
serum E2 levels. 
  
77 
 Statistical Test: IV = Serum SDPs; DV=Serum E2; 
 Statistical Test = Ti = θi + εi  
Random Effects Model 
The graphical outline below (Figure 7) is an indication of how various factors 
influence the mean effect in the REM. This provides an ability to generate even more 
reliable data.  
 
Figure 7. Random Effects Model. The observed effect T1 (▄) is sampled from a 
distribution with true effect θ1 (●), and variance σ
2. This true effect θ1, in turn, is sampled 
from a distribution with mean μ (♦)and variance τ2. Source: Borenstein, M., Hedges, L., 
Higgins, J., & Rothstein, H. (2009). Meta analysis, Fixed-Effects vs Random-Effects. 
Introduction to Meta-analysis. John Wiley & Sons, Ltd. “with permission” 
 
The following formula provides some context regarding the calculations as they 
effect, μ = mean of all true effects, ε1= within-study error, ζ1 = between-study error 
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(Borenstein, Hedges, & Rothstein, 2007). An observed effect, the following formula is 
applicable and will be useful in arriving at this statistical measure: 
Ti = θi + εi = μi + ζi + εi     (Borenstein, Hedges, & Rothstein, 2007) 
Subsequently, employing and calculating the Q statistics will provide evidence of the 
total variance between studies. Q is represented through the following equation 
 (Bowden, Tierney, Copas, & Burdett, 2011).  
These formulas will be important in ensuring detail statistical analysis. These 
formulas also help to eliminate any errors ‘in studies and between studies’ (Borenstein, 
Hedges, & Rothstein, 2007). Formulas reduce the potential for confounding which could 
influence the degree of reliability and validity within the output data. These conditions 
will be evaluated in subjects diagnosed with and had been treated for CaP at various 
stages of the disease. The REM is therefore the most suitable method that will be 
employed in this study, which will allow understanding the true effect of the separate 
interventions, subsequently combined and as they would be defined throughout a more 
expansive population.  
Consumption of soy based products at different levels and concentrations have 
been used to determine any relationship between and chemoprotective capacity relating 
to both newly diagnosed and hormone resistant CaP individuals. The use of meta-analysis 
for this project provided an opportunity to employ different statistical tools to assess the 
ES of the treatment or examined intervention. It is the prudent tool to use in this type of 
study as it allows for the analysis of a greater volume of subjects among several studies, 
which are then analyzed simultaneously. The benefit of this analytical tool is in the 
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aggregate data obtained which represents the magnitude and direction of the intervention 
effects throughout all the applied studies (Wilson, 2010). This aggregate will 
consequently provide better research data on the effect of the intervention (Wilson, 
2010).  
Utilizing meta-analysis allows for a detailed assessment of the influence of the 
independent variable (IV) SDPs on the dependent variables (DV) which includes PSA 
and E2. Age and other exposure factors were controlled during the analysis process and 
therefore the data output was not affected or influenced by those factors (Wilson, 2010). 
ES was determined using OR and other applicable statistics, including the standardized 
mean difference (SMD), correlation coefficient (CC), and Hedges’ g (Wilson, 2010). It 
was necessary that these standardized indexes be compared across the various studies. 
They represented both magnitude and direction of the relationship investigated in the 
studies analyzed and will be independent of sample sizes (Wilson, 2010). The meta-
analysis software was able to compute ES through input of the means and standard 
deviation data (Borenstein et al., 2007). However, this ability to use the software 
interchangeably, can allow for individual usage while examining the relationship between 
SDP intake and serum PSA and E2 levels (Neill, 2006). The use of the SMD for ES 
calculation was obtained by dividing Differences in Score by the SD of applicable scores 
(Neill, 2006). A presentation of the number of studies and effects used to generate the 
meta-analysis and subsequently the ES and the CI will assist in valuing the reliability and 
consistency presented through the ES mean (Neill, 2006).  
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Analysis using the CMA software provided greater statistical reliability and 
validity to the presented data. The result is the production of high quality reliable and 
valid data. Presentation of the research design and methodology is further in this chapter.   
Effect size computation formula: 
 
There are also other statistical programs such as SPSS and SAS that could 
effectively compute this study’s data output. However, the CMA software presented 
earlier in this discussion, provides extensive analytical scope and was employed to 
conduct all analysis. As an analytical tool it has all the required data applications that can 
account for each measure of effect being determined (Becker, 1999). This is in fact 
similar to calculating the degree of association between the independent variables and the 
dependent variables (Becker, 1999). The ability to compare analysis using different 
methods to achieve the goals can provide greater validity and reliability to the generated 
results.  
The statistical REM presents an opportunity to have a correlational deduction of 
the ES of an individual intervention (Becker, 1999; Wilson, 2010). This study employed 
OR using REM to define the correlation between variables. Other ES statistical methods 
used included Hedges’ g, correlation r, and SMD (Konstantopolous, 2006). These 
methods were applicable for this study as the selected RCTs are defined through 
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treatment and control effect in different groups within the studied populations. Both 
statistics are included among several accounted for in the CMA software. The formula 
used for calculating SMD is 
(Cochranes Handbook, 2010).  
 The SMD formula is also a representation of the expression of the size of the 
intervention effect in each study relative to any variability that has been observed in a 
particular study (Cochranes Handbook, 2010). In that context and in relation to ANOVA, 
Eta squared ((h
2
) which represents total variance of an effect will be determined 
employing the formula 2 = SSeffect / SStotal (Neill, 2006). In this formula SSeffect = ratio 
of the effect variance and SStotal = total variance (Neill, 2006). However, the number of 
independent variables accounted as well as the number and size of the effects (Becker, 
1999) are influenced by p
2
. Variation in the size of the different SSeffect will also 
influence the interaction effect result (Becker, 1999). Therefore, by using the above 
method expressed earlier relating to variance exclusion by (Bowden, Tierney, Copas, & 
Burdett, 2011) formula and the access to the professionally designed CMA statistical 
software then the results should be able to demonstrate validity and reliability.  
Internal and External Validity 
Meta-analysis supplements considerably more validity and reliability to the data. 
This supplementation has resulted in an increased use of meta-analysis especially in the 
fields of medicine and public health where the effect of an intervention is the pertinent 
response that is being sought. While there are weaknesses to the application of meta-
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analysis, the process can be considered valid and reliable and therefore, will prove a 
valuable tool in this analytical process. Added validity and reliability will also be derived 
from employing applications such as multiple regression to conduct aspects of the data 
analysis. Adding to the validity and reliability of the data, will be the coding and the scale 
used in conducting this research process. The continuous scale will be employed for this 
process, since there will be an opportunity to consider the difference in means between a 
treatment and a control group (Cochrane Collaboration, 2002). The value of having the 
presence of associated data relating to sample size (s), mean (m) and standard deviation 
data (SD) available from the research studies can also be appreciated as implied by 
(Cochrane Collaboration, 2002), as invaluable to the employment of the continuous meta-
analysis scale. While there might be immediate access to obtaining the standard deviation 
from some studies it can easily be obtained from statistical manipulation of other 
important variables such as the standard errors, confidence intervals, t-statistics, and p-
values (Cochrane Collaboration, 2002). Use of the professionally developed CMA 
(MetaStat, 2007), software will be applied throughout this research.  
Summary and Transition 
This chapter presented important aspects of the research including the design of 
the research process. Also addressed were the method of meta-analysis employed for this 
study and the appropriateness of this method for this process. Chapter 4 will focus on 
data presentation, interpretation of the results of the findings from the meta-analysis, 
while Chapter 5 will focus on discussing those findings and making recommendations 
based on those results. The conclusions that will be presented in Chapter 5, are those that 
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relate to the value of SDPs in alleviating the burden of CaP among the studied 
population. Hopefully, the findings will generate invaluable recommendations that can 
influence ‘positive social change’ within the broader community and even globally.  
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Chapter 4: Study Findings 
The purpose of this study was to determine the cumulative effect of genistein and 
daidzein intervention on serum PSA and serum E2 levels in American men. This is a 
cohort in which such analysis had not previously occurred. Guided by the principles of 
primary and secondary prevention and the newly conceptualized model of cancer 
prevention (DPIM), I sought to answer whether intake duration and concentration of 
SDPs directly influence magnitude and direction of CaP response. A selected group of 
eight RCTs of SDP CaP chemoprevention provided the data used in this study. These 
studies represented interventions designed to prevent or delay progression of recently 
diagnosed CaP disease or hormone-refractory CaP in men between 50–85 years old. This 
chapter includes the characteristics of the randomized clinical trials, and the description 
and tabulations of the hypotheses tested.  
Characteristics of Randomized Clinical Trials 
Information presented in this study includes data from eight (8) selected published 
RCTs of men who have undergone SDP chemoprevention for newly diagnosed CaP, 
hormone-refractory CaP and those at high risk for the disease following pathological 
analysis. Studies had pre- and posttest information on at least one of the dependent 
variables, PSA and E2, in order to be included. The studies selected were among some of 
the most recent studies examining the association between SDPs and CaP 
chemoprevention and the correlation to serum PSA and serum E2 levels. The studies 
were published in peer-reviewed journals and dated from 2004 – 2012. Seven (7) trials 
were conducted in the USA and one was conducted in research centers across Japan. The 
  
85 
sample yielded 530 male participants ranging between the ages of 50-85 years who 
matched selection criteria and completed baseline study requirements. The study 
accounted for a decline in participants during follow-up and the analysis process.  
The sample represents those that completed the clinical trial as both experimental 
group and controls. Participants represented several ethnic groups including European 
Americans, African Americans, Japanese Americans, Japanese, and Hispanics. However, 
European Americans dominate the study samples and the group for which this analysis 
needed to best address ES, African Americans, was not highly represented. Men with a 
history of CaP with increasing PSA levels, and subjects with CaP diagnosis and with 3 – 
6 months prior to surgical intervention, those monitored through active surveillance, and 
HRC subjects have been included in this study. All groups have contributed to the 
intervention and placebo groups that are the foundation of the study’s conceptualization 
in relation to chemoprevention from SDPs. One RCT study reported an average age of 
49.8 years old (White et al., 2010). Inclusion of this study should not significantly 
influence data analysis. All studies reported data collection at baseline and 3 month 
intervals. Incomplete study data due to non-compliance with study protocol following 
selection and study commencement affected some study results. The lowest number of 
participants in one study was 28 and the largest 158.  
Table 1 provides a description of information abstracted from the eight studies 
that were used to conduct the meta-analysis. Populations represented included those who 
responded either positively or negatively within treatment group where intervention was 
conducted. The odds of benefiting from intervention over placebo was then analyzed. The 
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table was generated using meta-analysis and the REM statistics. This provided evidence 
that contrasted the odds between the intervention and placebo groups in relation to 
administering or lack of intervention. Studies 4 – 6 provided information on E2 response 
to SDPs. Six (6) studies 1-3 and 6-8 provided evidence for PSA response to SDPs. The 
odds of benefiting from SDP intervention in the Adams et al. (2004) study are 0.576 
times more likely than the placebo. Benefit from SDP intervention is also seen in the 
studies by Carmody et al. (2008), Schroeder et al. (2005), and White et al. (2010) 
(OR=0.510, OR=0.667, and OR=0.700, respectively). However, the benefit of SDP 
intervention is not seen in the Dalais et al. (2004), Hamilton-Reeves et al. (2004), and 
Kumar et al. (2007) studies; the odds of SDP intervention influencing E2 levels are not 
significantly different from those of the placebo group. These statistics are consistent 
with OR analysis carried out using 2x2 contingency tables for hypotheses testing to 
examine intervention or placebo on treatment and control groups. These findings using 
SDPs as independent varialbes and PSA or E2 as dependent variables were determined 
using both meta-analysis and 2x2 tables and both methods yielded statistical significance.  
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Table 1 
Events among Treatment and Placebo Groups to Determine OR and other Statistics by 
PSA or E2 Outcome 
 
 PSA Outcome E2 Outcome 
Study 
Authors 
Positive 
Exposure 
Treatment 
Total 
n 
Exposed 
Positive 
Exposure 
Placebo 
Total 
n 
Placebo 
Positive 
Exposure 
Treatment 
Total 
n 
Exposed 
Positive 
Exposure 
Placebo 
Total 
n 
Placebo 
Adams et 
al., 2004 
34 17 47 14 - - - - 
Carmody et 
al., 2008 
10 17 5 14 - - - - 
Dalais et al., 
2004 
7 8 8 8 - - - - 
Hamilton-
Reeves, 
2007 
- - - - 4 12 0 17 
Kumar et al., 
2007 
- - - - 3 22 1 27 
Miyanaga et 
al., 2011 
3 75 2 78 14 33 16 47 
Schroder et 
al., 2005 
3 17 4 16 2 24 3 25 
White et al., 
2010 
14 24 8 25 18 25 7 25 
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Among the studies selected for this meta-analysis, experimental participants 
included those who had shown an increase in PSA levels following radical prostatectomy 
or radiotherapy, participants who had recently undergone prostate biopsy and histological 
analysis of the biopsied tissues, and men who were recently diagnosed through prostate 
biopsy and histological analysis, above normal serum PSA levels in defined age groups, 
pathology with CaP based on a defined inclusion Gleason Score and active surveillance. 
These criteria have been important in contributing to the foundation of the study’s 
conceptualization in relation to CaP chemoprevention from SDPs.  
Statistical Meta-Analyses 
The use of the REM in determining the ES and consequently the magnitude and 
direction of the intervention accommodate all the in-study and between study concerns. 
The REM accounts for any variance or bias in or between studies during the analysis 
process. Bias was observed in the participant selection process through either low or non-
inclusion of some minority groups, especially African Americans who experience a 
higher CaP incidence and disease burden (ACS, 2012).  
The data analysis tool employed for conducting all aspects of this study was meta-
analysis using OR statistic and following the constructs of the REM. This analysis was 
able to address all univariate, multivariate and ES analysis. ES is important in 
determining the magnitude and direction of the intervention. Two of the studies 
accounted for more than two experimental groups and were therefore able to contribute 
more value to the computed overall cumulative effect of genistein and daidzein on PSA. 
Three (3) studies reported on E2 values pre- and postintervention and therefore were used 
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to determine the effect of dietary and serum isoflavones levels on serum E2 levels. Seven 
(7) studies reported on pre and post-test information on PSA. Results were determined on 
the intervention effect response using genistein and daidzein. OR analysis was employed 
to determine the ES of the treatment intervention with dietary SDPs and to understand the 
correlation between dietary SDP, serum SDP levels, and serum PSA and E2 levels when 
compared between treatment and placebo subjects. When using OR for ES determination 
the results are defined through small = 1.50, medium = 2.50 and large = 4.50 odds ratio 
that there is some odds that benefits from a treatment intervention might or might not 
occur (Goldin, 2007). The ES as indicated was determined using the OR process but 
other logarithmic approaches that corrected for bias in the data output were determined 
from LogOdds Ratio, Variance, and Standard Error calculations.  
Research Questions and Hypotheses 
Research questions were answered using REM OR meta-analysis and OR 2x2 
contingency table statistics. Both meta-analysis and 2x2 table computation resulted in 
similar OR statistic results. The cumulative ES value from the meta-analysis provides 
evidence that favours intervention. Intervention subjects showed that both PSA and E2 
responded inversely to SDPs which would represent an inverse relationship.  The output 
data was generated using CMA software for ES and magnitude and direction of 
individual study effect and for cumulative study determination. Odds ratio (OR) statistic 
for correlation between independent and dependent variables based on the research 
questions was performed using a 2x2 contingency table. Other statistics including 
Hedges’ g, SMD and correlation were also used for meta-analysis data output (MetaStat, 
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2008). All the studies selected had relevant data on the included variables. Independent 
variables genistein and daidzein, and dependent variables PSA/E2 values were abstracted 
from each individual study.  
Odds (OR) of the effect of genistein and daidzein on the level of PSA and E2 as 
evidence of chemoprevention of CaP are presented through the following research 
questions, hypothesis and OR calculations. The OR provides information on the odds and 
not the probability of an event occurrence within the treatment group. However, the Cox 
Index which is determined through meta-analysis has been acknowledged as providing 
ES information that is known to be unbiased and also provides the best information on 
ES using continuous variables (TEA, 2011). 
Research Question 1: 
Is there a correlation between dietary SDPs and serum SDP levels? 
Null Hypothesis H1o: There is no correlation between dietary SDP levels and 
serum SDP levels. 
Alternative Hypothesis H1A: There is a correlation between dietary SDP levels 
and serum SDP levels.   
Statistical Analysis:   
As shown in Table 2, the OR = 0.5957 implies that the untreated SDP group 
would be more likely to not experience change in serum SDP levels. Therefore the odds 
are that dietary SDP levels more likely  influence a change in the serum SDP levels 
within the treatment group. Changes in serum SDP levels are more likely a direct result 
from the intervention and not a chance occurrence This OR also indicates that at 95% CI 
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there is a 0.2588 to 1.3712 increase of a positive outcome in the treatment group, 
although this increase at the 5% level is not statistically significant (MedCalc, 2013).  
This odds ratio therefore supports rejecting the Null hypothesis.  
Table 2 
Odds Ratio and 95% C.I. between Dietary SDP and Serum SDP Levels 
 
Research Question 2: 
Is there a correlation between dietary SDPs and serum PSA levels? 
Null Hypothesis H2o: There is no correlation between dietary SDP levels and 
serum PSA levels. 
Alternative Hypothesis H2A: There is a correlation between dietary SDP levels 
and serum PSA levels.   
Statistical Analysis: 
As shown in Table 3 OR = 0.6667 and implies that the untreated SDP group 
would be more likely to not experience change in serum PSA levels when compared to 
the treatment group. Therefore the odds are that dietary SDP levels more likely influence 
a change in the serum PSA levels within the treatment group. Changes in PSA level are 
more likely a direct result from the intervention and not a chance occurrence. This OR 
also indicates that at 95% CI of 0.1013 to 4.3878 there is some effect from treatment 
 SDP Serum 
Outcome 
  
OR 
 
95% CI 
 Positive Negative Odds   
SDP Yes 34 17 34/17   
SDP No 47 14 47/14   
Totals 81 31 (34/17)/(47/17) 0.5957 [0.2588, 1.3712] 
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although outside the statistical significance level at 5% (MedCalc, 2013). This odds ratio 
therefore supports rejecting the Null hypothesis.  
Table 3 
Odds Ratio and 95% C.I. between Dietary SDP and Serum PSA Levels 
p-value=0.018 
 
Research Question 3: 
Is there a correlation between dietary SDPs and serum E2 levels? 
Null Hypothesis H3o: There is no correlation between dietary SDP levels and 
serum E2 levels.  
Alternative Hypothesis H3A: There is a correlation between dietary SDP levels 
and serum E2 levels.  
Statistical Analysis:  
Table 4 indicates the OR = 0.4259 and implies that the untreated SDP group 
would be more likely to not experience change in serum E2 levels when compared to the 
treatment group. Changes in E2 level are more likely a direct result of the SDP 
intervention than from chance occurence. This OR also indicates that at 95% CI there is a 
0.0362 to 5.0055 increase of a positive outcome within the treatment group. This also 
 Serum PSA 
Outcomes 
  
OR 
 
95% CI 
 Positive Negative Odds   
SDP Yes 22 3 22/3   
SDP No 22 2 22/2   
Totals 44 5 (22/3)/(22/2) 0.6377 [0.1013, 4.3878] 
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indicates a CI within the 5% level and therefore statistically significant (MedCalc, 2013). 
This odds ratio therefore supports rejecting the Null hypothesis. 
Table 4 
Odds Ratio and 95% C.I. between Dietary SDP and Serum E2 Levels 
p-value=0.050 
Research Question 4: 
Is there a correlation between serum SDPs and serum PSA levels? 
Null Hypothesis H40: There is no correlation between serum SDP levels and 
serum PSA levels.  
Alternative Hypothesis H4A: There is a correlation between serum SDP levels and 
serum PSA levels.  
Statistical Analysis:  
As shown in Table 5 an OR = 0.7000 implies that the untreated SDP group would 
be more likely to not experience change in serum PSA levels. Therefore the odds are that 
serum SDP levels is likely to influence a change in the serum PSA levels within the 
treatment group. Changes in serum PSA level are more likely a direct result from the 
intervention and not a chance occurrence. This OR also indicates that at 95% CI there is a 
0.2024 to 2.4207 increase of a positive outcome in the treatment group at the 5% 
 Serum E2 Outcomes   
OR 
 
95% CI 
 Positive Negative Odds   
SDP Yes 23 2 23/2   
SDP No 27 1 27/1   
Totals 50 3 (23/2)/(27/1) 0.4259 [0.0362, 5.0055] 
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confidence level and therefore not statistically significant (MedCalc, 2013). This odds 
ratio therefore supports rejecting the Null hypothesis.   
Table 5 
Odds Ratio and 95% C.I. between Serum SDP and Serum PSA Levels 
p-value=0.018 
Research Question 5: 
Is there a correlation between serum SDPs and serum E2 levels?  
Null Hypothesis H50: There is no correlation between serum SDP levels and 
serum E2 levels. 
Alternate Hypothesis H5A: There is a correlation between serum SDP levels and 
serum E2 levels.   
Statistical Analysis:  
As shown in Table 6 an OR = 0.641 implies that the untreated SDP group would 
be more likely to not experience change in serum E2 levels when compared to the 
treatment group. Changes in serum E2 level are more likely a direct result from the 
intervention and not a chance occurence. The OR also indicates that at 95% CI there is a 
0.1042 to 3.9447 increase of a positive outcome within the treatment group. This increase 
is at the 5% level and is statistically significant (MedCalc, 2013). This OR therefore 
supports rejecting the Null hypothesis.  
 Serum PSA 
Outcomes 
  
OR 
 
95% CI 
 Positive Negative Odds   
SDP Yes 28 8 28/8   
SDP No 25 5 25/5   
Totals 53 13 (28/8)/(25/5) 0.7000 [0.2024, 2.4207] 
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Table 6 
Odds Ratio and 95% C.I. between Serum SDP and Serum E2 Levels 
p-value=0.050 
Cumulative Effect of SDP on PSA and Estradiol 
Six (6) RCTs were analyzed for consideration of the cumulative response to 
treatment (Figure 8) from SDPs on serum PSA level. The SDP cumulative ES on sPSA 
resulted in a positive correlation (OR=0.507, 95% CI [0.288, 0.891], p=.018). Another set 
of five (5) studies were analyzed for consideration of the cumulative response to 
treatment (Figure 9) from SDPs on sE2 level. The SDP cumulative ES on sE2 also 
showed a positive correlation (OR=0.366, 95%CI [0.134,1.002], p=0.050). The ES of 
each study’s dependent variable is represented by a square (■) where the size of the 
squares contribute more and length and thickness of lines provide evidence of 
contribution of each study towards cumulative ES. The diamond (♦) represents the 
cumulative ES for the set of six (6) studies showing the PSA response and the other set of 
five (5) studies showing E2 response. Further evidence of these correlations were 
determined through other ES statistics and Forest Plots also generated by the meta-
analysis software. These confirmatory findings will be discussed in Chapter 5. The 
overall ES favoring the treatment or the placebo group is shown in the Forest Plot for the 
PSA outcome (Figure 8) and E2 outcome (Figure 9).  
 Serum E2 
Outcomes 
  
OR 
 
95% CI 
 Positive Negative Odds   
SDP Yes 75 3 75/3   
SDP No 78 2 78/2   
Totals 153 5 (75/3)/(78/2) 0.641 [0.1042, 3.9447] 
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Study Authors Statistics for each Study Odds ratio and 95% CI 
Odds  Lower  Upper  
Ratio  Limit  Limit  Z-Value p-Value 
Adams 0.424  0.169 1.062 -1.831 0.067 
Carmody 0.389  0.090 1.673 -1.269 0.204 
Dalais 3.400  0.120 96.700 0.716 0.474 
Miyanaga 0.632  0.103 3.890 -0.495 0.620 
Schroder  1.524  0.290 8.014 0.497 0.619 
White   
Cumulative 
0.336  0.105 1.081 -1.829 0.067 
0.507  0.288 0.891 -2.362 0.018 
0.01 0.1 1 10 100 
Favors SDP  Favors Placebo  
Figure 8. Odds Ratios and 95% CI Effect Size of PSA Response to Phytoestrogen 
Treatment using REM Meta-Analysis 
  
97 
 
 
 
Study Authors Statistics for each Study Odds Ratio and 95% CI 
Odds  Lower  Upper  
Ratio  Limit  Limit  p-Value Z-Value 
Hamilton-Reeves  0.054 0.003 1.122 0.059 -1.886 
Kumar 0.244 0.023 2.527 0.237 -1.183 
Miyanaga 0.700 0.280 1.752 0.447 -0.761 
Schroder 1.500 0.228 9.872 0.673 0.422 
White  
Cumulative  
0.151 0.044 0.520 0.003 -2.999 
0.366 0.134 1.002 0.050 -1.957 
0.01  0.1 1 10 100 
Favors SDP Favors Placebo 
Figure 9. Odds Ratios and 95% CI Effect Size of Estradiol Response to Phytoestrogen 
Treatment using REM Meta-Analysis 
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Heterogeneity 
The use of heterogeneity provides a measure of inter-study variability, a major 
consideration for meta-analysis. Heterogeneity helps to measure any inconsistencies that 
might be present within the results obtained from analysis of the data within the six 
studies used in each of the meta-analysis (StatsDirect Limited, 2011). The Heterogeneity 
statistic in this study using the REM and odds ratio for ES analysis of PSA response was 
significant at p=0.019 (Test of Null, 2-Tail). The Heterogeneity statistic using the REM 
to calculate the OR for ES determination of E2 response was significant at p=0.049 (Test 
of Null, 2-Tail). This heterogeneity function is used to denote the weight of a particular 
study and I-squared (I
2
). I
2 
represents the percentage variation across studies due to 
heterogeneity and not chance (StatsDirect Limited, 2011). Heterogeneity is considered to 
influence when I
2 
reaches 75%.   
Heterogeneity is represented statistically by Cochran’s Q. Q can be calculated by 
employing the combined sum of the difference of squared effects of an individual study 
and the effects which have been pooled across the studies (StatsDirect Limited, 2011). 
The weight of the studies’ effect is also based on the pooling of those studies. Q‘s 
distribution is statistically similar to the chi-square distribution with k being the number 
of studies minus 1 degree of freedom (df). Because of the small amount of studies used in 
this meta-analysis Q might not be very valuable for testing heterogeneity. Q could under 
compensate in this study because of the small number of studies, or it could also over-
compensate if the meta-analysis consisted of a large number of studies (SDL, 2011). I
 2 
is 
therefore the important statistic that helps in the testing of heterogeneity. I
2
 indicates the 
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percentage of variation that is seen across studies and is due to heterogeneity 
rather than to chance (SDU, 2011). Heterogeneity is also important in that it includes 
statistical, methodological, and clinical types of heterogeneity. Since heterogeneity 
relates to those differences or variability that are present among different studies its use 
provides value to the output data. Key differences that are important between study 
participants are among those characteristics that account for the clinical heterogeneity 
and is important to the foundation of this analysis process (Bandolier, 2007). Other key 
differences between studies are also seen in areas such as the participants, the 
intervention employed and the observed outcomes (Bandolier, 2007). The Q statistic is 
calculated by employing the combined sum of the difference of squared effects of an 
individual study and the effects pooled across studies (StatsDirect Limited, 2011). The 
weight of the effects are mainly based on those pooled studies.  
Important differences that existed between study participants included 
characteristics that account for clinical heterogeneity and are the foundation of this 
analysis (Bandolier, 2007). Key differences between studies are in areas such as the 
participants, the intervention employed and the observed outcomes (Bandolier, 2007). 
These are areas where the use of the random effect model becomes valuable. Other ES 
calculations were done using different statistical methods including SMD, correlation, 
Hedges’ g and risk ratio. The analyses using Hedges’ g and correlation are presentd as 
Figures 11 and 12. They provide similarity to the correlation which had been determined 
by odds ratio statistic.  
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Summary and Transition 
Consistent with the purpose of the study to determine the cumulative effect of 
genistein and daidzein intervention on serum PSA and serum E2 levels, five research 
questions were answered using OR and meta-analysis. The first research question sought 
to determine if the correlation between dietary intake of SDPs translated into equivalent 
absorption of serum SDPs. The odds ratio indicated a significant ES in the pooled 
analysis of eight studies, and the null hypothesis was rejected. Overall, there was a 
correlation between dietary SDP and serum levels of SDP. The second and third 
questions sought to answer whether dietary SDPs were correlated with serum PSA and 
E2 levels. Both the second and third null hypotheses were rejected as significant 
correlations were determined based on OR for PSA at p=0.018, and OR for E2 at 
p=0.050. The fourth and fifth research questions sought to answser whether serum SDPs 
were correlated with serum PSA and E2 levels. Findings supported rejecting both null 
hypotheses. There was a direct correlation betweeen serum SDP levels and response of 
serum levels of PSA significance p=0.018, and E2 p=0.050.  
The correlations were supported by evidence from OR 2x2 contigency table 
analysis of treated and non-treated individuals and through OR, correlation, Hedges’ g 
and SMD Forest Plot evidence. The cumulative ES supported by all the evidence 
indicates that there were signifcant correlations between intervention compared to 
placebo groups. Chapter 5 will provide further discussion on the results of these findings, 
the implication for positive social change, limitations of the study and an overall 
interpretation of the results.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
Overview 
The purpose of this study was to determine through cumulative evidence the 
effect of using the SDPs genistein and daidzein on PSA and E2, important markers for 
early diagnosed CaP and HRC CaP incidence in American men, a cohort where such 
analysis has not previously occurred. The research process was guided by the principles 
of primary and secondary prevention and the DPIM (Michelin & Gutierrez, 2013). I 
sought to answer whether intake of SDPs directly influenced the magnitude and direction 
of PSA and E2 levels which were important in CaP response to therapy and outcome. 
Information for this study was obtained from selected published RCTs which used the 
named SDPs in chemopreventive intervention designed to prevent or delay cancer 
progression in recently diagnosed men or in men with HRCaP between 50–85 years old.  
This study was a quantitative analysis of information from selected published 
RCTs demonstrating the chemoprevention ability of soy derived SDPs. Analysis of the 
ES of the intervention in these studies was conducted employing meta-analysis. The 
independent variables are quintiles of the SDPs genistein and daidzein. The dependent 
variables included serum levels of E2 and PSA. The study sought to determine the ES in 
SDP dose-response intervention in the selected male populations during the therapeutic 
application for recently diagnosed and recurrent CaP, and the contribution of duration 
and concentration in determining the size and direction of action.  
These OR ES statistics provided reliability to the correlations seen in the OR data 
output. Other statistics that provide value and support the validity and reliability of the 
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OR data output includes both Z and p values. Tables 2 through 6 are 2x2 
tables that provide correlation of the response between independent and dependent 
variables. The observed OR is determined at 95% CI for correlation between variables. 
This provides valuable information on the intervention in relation to the 
untreated/placebo group. OR = 1 implies no significant difference between treatment and 
placebo group or no effect from treatment, where OR < 1 implies that the untreated group 
will be more exposed to experiencing a negative response. An OR > 1 implies that the 
treated group would more likely benefit from the intervention. 
Confirmatory and Transitory Evidence 
This study was guided by the principles of primary and secondary prevention 
following the DPIM (Michelin & Gutierrez, 2013). This model is described in Figure 3 
(page 15) and guided the examination of the research questions. These questions related 
to the chemoprevention of CaP using SDPs. The model showed the potential for 
therapeutic application. The direct influence of dietary SDPs on serum SDP levels and 
the strength and direction of treatment on serum PSA and E2 levels was important. Both 
serum PSA and E2 could influence CaP response and outcome. ES of treatment was 
determined using OR, SMD, correlation, and Hedges’ g statistics. 
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Table 7 
REM Statistics for Computing Effect Size and Heterogeneity 
Statistical Measures 
of Effect Size 
Meta-Analysis 
Model 
Effect 
Size 
value 
2 Tail 
Null 
Test p-
value  
Q I
2
 Variance 
       
Hedges’ g 
 
Hedges’g 
Random 
Effect(PSA) 
Random 
Effect(E2)  
-0.368 
 
-0.546 
0.019 
 
0.049 
3.792 
 
7.501 
0.000 
 
46.672 
0.010 
 
0.072 
Correlation 
 
Correlation 
Random 
Effect(PSA)  
Random 
Effect(E2) 
-0.184 
 
-0.280 
0.015 
 
0.035 
3.861 
 
8.251 
0.000 
 
51.519 
0.001 
 
0.004 
SMD 
 
SMD 
Random 
Effect(PSA) 
Random 
Effect(E2) 
-0.375 
 
-0.554 
0.018 
 
0.050 
3.747 
 
7.542 
0.000 
 
46.962 
0.011 
 
0.080 
OR 
 
OR 
Random 
Effect(PSA) 
Random 
Effect(E2) 
 0.507 
 
 0.366 
0.018 
 
0.050 
3.747 
 
7.542 
0.000 
 
46.962 
0.121 
 
0.836 
 
There was significant difference between intervention and placebo. This was seen 
in the OR REM produced forest plots (Figures 8 & 9), which favored intervention over 
placebo. Other statistical ES tests including SMD, correlation and Hedges’ g provided 
similar results. Forest plots representing Hedges’s g are shown on pages 107 and 108, and 
for correlation on pages 109 and 110. The test for heterogeneity in the study supported 
the results of ES analysis.  
Determining Q can compensate for the limitations that could affect the data 
obtained from the study. Accommodating limitations is possible using meta-analysis 
(SDL, 2011). I
 2 
is also an important statistic that helps in the testing of heterogeneity. It 
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indicates the percentage of variation that is seen across studies and which are 
due to heterogeneity rather than by chance (SDU, 2011). Importantly, there are different 
types of heterogeneity. These include statistical, methodological and clinical. 
Heterogeneity relates to the differences or variability that is present among different 
studies. In this study, I
2
 determined the estimate of effects in this study as represented 
through the several interventions. During this study, individual investigations sought to 
determine the effect of an intervention compared to placebo, indicating clinical 
heterogeneity (Bandolier, 2007). Importantly, several studies employed the research 
practice of adhering to the intention to treat (ITT) principle. This ITT allowed the 
researchers to follow the subjects for the length of the research process (Lachin, 2000). 
There are also important key differences between studies which are related to the 
participants, the intervention employed and the observed outcomes. Some of these were 
also observed in this study (Bandolier, 2007). Again, these are areas where the use of the 
random effect model becomes valuable in helping to resolve issues that could be 
associated with study differences.  
 The heterogeneity for studies used to determine the ES of PSA response with 
OR statistic is represented by Q value=3.747, Q(df) =5 and I
2
=0.000, supports the 
correlational significance determined through the ES analysis. The 2-tail null test for PSA 
shows a negative Z value of -2.362 and a p=0.018 (Figure 8). Heterogeneity for studies 
used to determine E2 response is represented by Q value of 7.542 Q(df)=4 and 
I
2
=46.962, supports the correlational assessment determined through the ES analysis. The 
2-tail null test for E2 shows a negative Z value of -1.957, and a p=0.050 (Figure 9). Some 
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heterogeneity was observed between studies when E2 response was 
determined. However, heterogeneity did not appear to influence either the results that 
were determined during PSA and E2 response to SDP intervention. Since the OR Z value 
-2.204 for PSA response is negative and outside the -1.96 and +1.96 normal distribution 
with a p value 0.028, then these values appear to support a rejection of the null 
hypothesis. There were no significant differences in the results obtained for PSA and E2 
response using other ES statistical analyses. Using SMD to determine ES for E2 response 
provided an overall p value of 0.050 and variance of 0.080 which as indicated is an effect 
that is within the p < 0.05 significance level. A statistical significant p value =0.050 
indicates the probability that any observed changes could be attributed to the intervention 
rather than by chance occurrence (Thisted, 2010). Similarly, the overall significance level 
for E2 determined from Hedges’g ES analysis is p = 0.027 (Figure 11). This implies a 
statistically relevant correlation between SDP treated group and placebo groups, but 
might still not provide sufficient evidence to eliminate some chance occurences (Thisted, 
2010).  
Overall, the data indicate that there is acceptance that intervention with SDPs for 
PSA reduction and influencing increases in E2 levels can be important for CaP 
chemoprevention. Such therapy can be accomodated within the putative model 
(Giovannucci, 1999) and has the potential for improving health outcomes. The 
correlation between dietary and serum SDPs, which results in an increase in the latter, 
appears to have some beneficial role in modulating both serum PSA and E2. With serum 
E2 maintaining a high level following intervention, the evidence supports its role as an 
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estrogen replacement for CaP therapy. As a natural alternative source, it could 
be effective in reducing present CaP incidence, especially in communities where 
economic status does not allow for available medical interventions.  
Interpretation of Key Findings 
In this study, eight RCTs were used to calculate the ES of SDP in a 
chemopreventive role in various conditions where the diagnosis of CaP was concluded. 
To conduct ES of the intervention, the CMA software was used. The adverse events 
within both treatment and placebo groups was used in a 2x2 cohort format to calculate 
OR for ES and magnitude and direction of treatment intervention using meta-analysis. 
REM was used in this study as it provided a more reliable approach for data analysis than 
the FEM. REM is able to mitigate differences that are present within and between studies. 
This accounts for the differences through a broader framework of understanding that 
studies were done under different situations with different populations. Figures 8, 9, and 
10 indicate individual and cumulative ES of treatment intervention. Table 8 reflect the 
different outcomes relating to PSA and E2 response from SDP intervention. The 
correlations seen between the DVs and IVs provides evidence of support or rejection of 
the Null hypothesis for the Alternative hypothesis. As indicated an increase in sSDP, and 
a subsequent decrease in sPSA and increase in sE2 then the Null Hypothesis is rejected. 
Other conditions relating to the acceptance or rejection of the Null hypothesis for the 
Alternative hypothesis are presented in the table.  
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Table 8 
Interpretation of Hypotheses Testing Results Using Random Effect Model Effect Size 
Hypothesis 
Testing 
Accept Null (T) Reject Null (F) Accept Alternative 
(T) 
Reject Alternative 
(F) 
 
Dietary SDPs 
 
↑ Serum levels  
 
↓ Serum levels 
 
↓ Serum levels 
 
↓ Serum levels 
 
Serum SDPs 
 
↑ SDP 
 
↑ SDP 
 
↓ SDP 
 
↓ SDP 
 
Serum PSA 
 
↓ PSA 
 
↑ PSA 
 
↑ PSA 
 
↓ PSA 
 
Serum E2 
 
↑ E2 
 
↓ E2 
 
↓ E2 
 
↑ E2 
 
The various relationships indicated above in figure 8 are also a reflection of the 
effect of dSDP and the serum level response of sSDP, sPSA and sE2. The cumulative 
response to dSDP intervention is provided in Figures 10 and 11. Figures 10 and 11 are 
representative Forest Plots that show the strength and direction of the contribution from 
each study’s effect to the overall treatment effect on both PSA and E2. The contributory 
effect of each study to the cumulative effect is identified through the size of each study’s 
representative square and length and thickness of the effect line. The effect of dSDP and 
subsequently sSDP appears to be significant and favors the use use of intervention during 
CaP therapy where PSA and E2 responses are beneficial. The effect response of both 
PSA and E2 to SDP over the time of the experiment are indicated in the two graphical 
representations. These results were used to confirm similar correlation obtained from OR 
analysis. Other ES statistics including Correlation and SMD were done and provided 
similar positive results favoring SDP intervention. While those ES provided values within 
  
108 
a different statistical context of a 95% CI all appeared to provide similar 
supportive evidence for rejection or acceptance of the null hypotheses.  
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Study Authors Statistics for each study Hedges' g and 95% CI 
Hedges'  Standard  Lower  Upper  
g error Variance limit limit Z-Value p-Value 
Adams -0.468 0.256 0.065 -0.970 0.033 -1.831 0.067 
Carmody -0.507 0.400 0.160 -1.290 0.276 -1.269 0.204 
Dalais 0.643 0.897 0.804 -1.115 2.400 0.716 0.474 
Miyanaga -0.252 0.509 0.259 -1.249 0.745 -0.495 0.620 
Schroder 0.238 0.462 0.214 -0.668 1.143 0.514 0.607 
White   
Cumulative 
-0.591 0.323 0.105 -1.225 0.042 -1.829 0.067 
-0.368 0.156 0.024 -0.674 -0.062 -2.354 0.019 
-1.00 -0.50 0.00 0.50 1.00 
Favors SDP  Favors Placebo  
Figure 10. Hedges’s g Assessment for Effect Size Statistic for PSA Response to Phytoestrogen  
Treatment using REM Meta-Analysis  
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Study Authors  Statistics for each Study  
 
Hedges's g and 95% CI  
Hedges’  Standard  Lower  Upper  
g error Variance limit limit p-Value Z-Value 
Hamilton-Reeves -1.568 0.831 0.691 -3.197 0.062 0.059 -1.886 
Kumar -0.766 0.647 0.419 -2.035 0.503 0.237 -1.183 
Miyanaga -0.194 0.255 0.065 -0.695 0.306 0.447 -0.761 
Schroder 0.220 0.522 0.272 -0.802 1.242 0.673 0.422 
White 
Cumulative  
-1.025 0.342 0.117 -1.695 -0.355 0.003 -2.999 
-0.546 0.278 0.077 -1.090 -0.001 0.049 -1.964 
-1.00 -0.50 0.00 0.50 1.00 
Favors SDP Favors Placebo 
Figure 11. Hedges’ g Assessment for Effect Size Statistic for Estradiol Response to Phytoestrogen  
Treatment using REM Meta-Analysis  
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Hedges’ g statistic using REM meta-analysis to test for E2 
heterogeneity resulted in a p value = 0.049 (Figure 11), significant at the 95% CI level. 
The analysis for E2 response determined that treated subjects had optimum response to 
SDP significant at the p=0.050 level. A similar positive response was determined 
regarding the PSA response to SDP intervention. Forest plots indicating the cumulative 
effect of SDP on sPSA and sE2 are provided in Figures 12 and 13 respectively. 
Correlation for PSA response was determined at the p=0.015 level. OR results had also 
suggested that there were changes in relation to PSA status, which would suggest benefit 
from the chemoprevention. Statistical significance for OR was determined to be p=0.018 
as previously reported. While lower PSA levels do not always infer improved health 
outcome during therapy, reduced levels can be seen as an important marker for overall 
therapeutic response (NCI, 2012). In fact, some factors including age of subjects, 
duration and concentration of treatment and size of experimental population could affect 
OR results. These results appear to support the goal of this study and are within the 
framework of the DPIM (Michelin & Gutierrez, 2013). The previous evidence may 
provide for effective implementation of chemoprevention prior to disease development. 
Findings from the various ES statistic supported rejecting the Null. These findings also 
indicated the potential ability to reduce PSA levels within the population through 
introduction of dietary SDP. The benefit of maintaining serum E2 concentrations also 
appears to be a valuable outcome from SDP chemoprevention.
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Study Authors Statistics for each Study Correlation and 95% CI 
Lower  Upper  
Correlation limit limit Z-Value p-Value 
Adams -0.227 -0.442 0.012 -1.863 0.062 
Carmody -0.251 -0.567 0.130 -1.297 0.195 
Dalais 0.320 -0.495 0.835 0.742 0.458 
Miyanaga -0.126 -0.553 0.355 -0.498 0.618 
Schroder 0.121 -0.327 0.524 0.517 0.605 
White   
Cumulative 
-0.288 -0.540 0.012 -1.882 0.060 
-0.184 -0.325 -0.036 -2.429 0.015 
-1.00 -0.50 0.00 0.50 1.00 
Favors SDP Favors Placebo 
Figure 12. Correlational Assessment for Effect Size Statistic for PSA Response to Phytoestrogen  
Treatment using REM Meta-Analysis  
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Study Authors  Statistics for each Study Correlation and 95% CI 
Lower  Upper  
Correlation limit limit p-Value Z-Value 
Hamilton-Reeves -0.622 -0.880 -0.082 0.027 -2.208 
Kumar -0.361 -0.751 0.216 0.215 -1.239 
Miyanaga -0.096 -0.331 0.150 0.445 -0.763 
Schroder 0.111 -0.384 0.556 0.672 0.424 
White  
Cumulative 
-0.462 -0.665 -0.195 0.001 -3.244 
-0.280 -0.504 -0.020 0.035 -2.104 
-1.00 -0.50 0.00 0.50 1.00 
Favors SDP Favors Placebo  
Figure 13. Correlational Assessment for Effect Size Statistic for Estradiol Response to Phytoestrogen 
Treatment using REM Meta-Analysis 
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This meta-analysis was conducted using exposure and non-exposure to treatment 
and placebo groups. The results from the various meta-analysis statistics showed 
differences in the between studies ES although all observed cumulative effect indicated a 
rejection of the null hypothesis. The symbol which is representative of the cumulative ES 
on the confidence level line was evidence of the correlation between SDP intervention 
and estradiol (E2) and PSA response. This information is presented in Figure 11 with 
graphical Forest Plot. The individual and cumulative contribution from each study is used 
in determining ES and magnitude and direction of treatment effect. The studies by 
(Carmody et al., 2008; Schroder et al., 2006; and White et al., 2010) appear to have 
significant influence on the overall presented data. The presented data output is also a 
representation of the effect of each study on the overall ES. This effect is repesented 
through larger squares and shorter lines that are shown on each line which represents an 
individual study. There appears to be no significant difference between the effects over 
time as indicated between the two graphical representations. To confirm results that were 
obtained from OR analysis, other ES statistics including Hedges’ g, correlation, and SMD 
were done. While ES values were represented in different context of a 95% CI it 
appeared that the overall evidence for rejection or acceptance of the Null hypotheses 
indicated through were supportive.  
Study Limitations 
Bias could be attributed to study population selection and size since either could 
influence data output. Evidence in the various studies show an increase in serum levels 
from baseline to study completion. These changes are important in the effect analysis that 
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is computed for independent and dependent variable effect. Implication from this study 
seem to indicate that the intervention using soy derived SDPs does have some effect on 
the treatment population. This difference was demonstrated through the analysis data on 
both treatment and placebo or control groups in this study. However, further research 
might be needed to determine the true value of genistein and daidzein the test 
compounds. Within the context of these results and the overall framework of the research 
model there was evidence that seem to indicate that there is value from the treatment. 
However, other limitations might have  resulted from issues with coding and data 
transferring for the required meta-analysis. The data reported in the studies might also be 
subjected to study bias and therefore did not provide the best evidence relating to benefits 
of therapy when subjected to meta-analysis. While duration as a moderating variable did 
not appear to have any significant effect on the magnitude and direction of the treatment 
as seen in Figure 1, possible longer duration might have some effect. Another important 
context to defining the significant difference between PSA treated and placebo groups is 
indicated where p= 0. 018 (Figure 8) determined by OR REM statistic, p=0.019 (Figure 
10) by Hedges’g REM statistic and p=0.018 determined by SMD REM statistic. These 
values represent the probability that the response to treatment is different from only 
chance ocurences. Statistical significance is observed at p values of < 0.01 or p < 0.001. 
Similarly, it is also important to define the significant difference between E2 in treated 
subjects and in untreated controls. Here, p=0.050 (figure 11) determined by OR REM 
statistic, p=0.049 (figure 12) determined by Hedges’g REM statistic, and p=0.050, 
determined by SMD REM statistic. Statistical significance observed at p values of < 0.01 
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or p < 0.001. Statistical significance to SDP intervention was obtained through values for 
PSA ES response at p=0.018 OR and for E2 ES at p=0.050 OR statistic. Statistical 
significance at the p≤0.05 level was therefore indicated from these statistics.   
Testing if studies used in the meta-analysis are looking at the same study effect is 
done by examination of the test for heterogeneity (Higgins, Thompson, Deeks, & Altman, 
2003). Heterogeneity is considered significant in determining the quality of this study. 
Other statistical analyses also reported some important p values. Correlational analyses 
using meta-analysis for PSA response provided a value p= 0.015 and variance = 0.001 
and the cumulative meta-analysis using Hedges’g statistic for heterogeneity among 
studies for E2 response indicated a p value = 0.050 and variance = 0.072. These findings 
indicated that there were some differences in response between experimental and placebo 
groups. The significance of the analysis is supported by the fact that all statistics used in 
this meta-analysis resulted in significant p values below p≤0.05.   
Effect Size Analyses 
ES were calculated adjusting for moderator variables, including median age, 
duration of intervention, ethnicity of participants, differences between baseline and post-
study PSA, baseline and post-study E2, and any correlation between changes following 
SDP chemoprevention. While there were six studies that provided information on serum 
PSA levels at baseline and other time points during the study, only five studies provided 
information that could provide context to be used regarding the influence of SDP on E2 
during ES data analysis. However, ES data did not change after input of any of the 
moderator variables including SDP duration or quantity provided during the experimental 
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intervention. There were also no significant differences in the data obtained using the 
FEM and REM (models). The data presented in this discussion were obtained using 
statistics determined through the REM which was mentioned earlier in Chapter 1 and 
then discussed extensively in Chapter 3. Meta-analysis used the REM since it offered the 
opportunity for providing more reliable and valid data.  
As a reminder, the purpose of this study was to determine through cumulative 
evidence the ES of intervention with genistein and daidzein SDPs on serum PSA and E2 
levels in males who were experiencing rising PSA levels, undergoing active surveillance 
following CaP diagnosis, and males recently diagnosed with CaP or with hormone 
refractory CaP. The study was designed to look at the magnitude and direction of the 
output ES in response to SDP chemoprevention. The ES observation was made through 
changes seen primarily among American males, a cohort where such meta-analysis had 
not previously occurred. The conceptual premise of the study was guided by the 
principles of primary and secondary prevention adhering to the newly conceptualized 
DPIM (Michelin & Gutierrez, 2013). The study also sought to answer whether intake 
duration and concentration of SDPs had a direct influence on the magnitude and direction 
of E2 and PSA response. The observations from this meta-analysis reflect changes in 
PSA and E2 levels that occurred as a result of dietary SDP intervention during the 
duration of the RCTs. Additional observations to correlate these changes in PSA and E2 
levels during the course of regular treatment could provide further evidence of correlation 
with actual disease outcome and whether there is improvement in health status.  
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Data for this study were obtained from selected published RCTs of SDP 
intervention designed to prevent or delay hormone-refractory CaP and recently diagnosed 
CaP in males between 50–85 years old. The REM statistical method was used in the 
process the data analysis and also provided information on heterogeneity between 
indivudal study intervention and cumulative meta-analysis study results. It was noticeable 
that REM did not differ significantly from the FEM statistics. There was an observed 
difference in the REM and FEM findings comparing treatment and placebo groups in 
relation to the total study populations. Hedges’ g and SMD statistics afforded additional 
context assisted in the determination of ES by providing confirmatory analysis when OR 
was used for ES statistical analysis. Information obtained from OR statistic was used to 
determine rejection or acceptance of either the null or the alternative hypothesis. 
Cumulative OR statistic from the REM analysis is provided in Figure 8 (Page 97).  
The SD measure is determined based on similarity to values between -1 to 1. An 
ES value closer to 1 is a determination that there is a larger difference in effect between 
treatment and placebo group involved in the study. When ES was determined using 
Hedges’s g, analysis of data reporting E2 levels, this showed a positive relationship. The 
ES of studies by Miyanaga et al. (2011), Kumar et al. (2007), White et al., (2010), 
Schroder et al., (2005), and Hamilton-Reeves et al. (2007) are represented by g = -0.194, 
-0.766, -1.025, 0.220, and -1.568, respectively. Here, all values fell below .50 which 
would imply a SD of one-half (1/2) while 1.0 would be representative of a SD of 1.0 
between the two groups. However, the negative values between the groups that reported  
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predominantly on PSA levels indicate a decisive lower SD between treatment and 
placebo groups. Heterogeneity testing (using Hedges’ g REM) indicated a cumulative Q 
value of 3.792 (p=0.019, df (Q)=5, and I
2
=0.000) and ES of -0.368. The findings from 
heterogeneity testing implied that there was a 5% chance at 95% CI of a positive effect 
due to SDP intervention. Also, the effect seen in this study was within that probability of 
significance determined by the p=0.019 value using OR statistic.  
Recommendations for Future Research 
The DPIM proposed in this study by Michelin and Gutierrez (2013) provides an 
avenue for exploring early intervention and subsequent therapeutic strategies with disease 
onset. Prior frameworks including the putative model proposed by Giovannucci, (1999), 
do not appear to consider early established dietary standards and a public health context 
is not the conceptualized focus. The DPIM allows for intervention using SDPs at 
different stages of CaP etiology. Early dietary interventions could prevent or delay the 
development of PINs. The value of PINs and their importance to CaP etiology was 
presented earlier in this research. SDP intake prior to PIN development and clinical 
cancer diagnosis that is accompanied by increasing PSA levels would therefore be 
prudent. With progression continued inclusion of dietary SDPs and subsequent increase 
in serum SDP levels could also be suggested. Research is required to determine the 
optimum serum level at which SDPs afford the best health outcomes. The cumulative OR 
results do not appear to suggest any significant difference between treated and placebo 
groups in lowering serum PSA levels. However, there is significance in the levels of E2 
that results from intervention. Further research is required to understand in greater detail 
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the role of E2 in cancer etiology, and how SDPs can positively influence its serum levels. 
However, based on the results of this research a more prudent approach would be to 
begin intervention through the development of established dietary levels which appear to 
have value in observed relationship between SDPs, PSA and E2 levels.  
The findings from this study indicate that there is an inverse correlation between 
serum SDPs and response of serum E2 levels. This could be supportive evidence for the 
chemopreventive role of dietary isoflavones. The DPIM therefore appears to be better 
suited for chemoprevention at an earlier stage and potentially be a more effective 
preventative approach. An indication for SDP intervention which appears to be beneficial 
based on results from the research is that relating to E2 levels. E2 levels which represent 
an estrogen which is found in minute quantities within the male can be seen as a health 
hazard if there is an imbalance and larger than normal quantities are present. Within the 
articles that focus on E2 levels at pre and post-intervention, there appear to be significant 
change in E2 serum concentration levels which with ES measure using OR statistic. The 
evidence of higher E2 levels post-intervention may suggest greater odds for increasing 
and maintaining higher levels of E2 subsequent to SDP intake and increase in serum 
levels. E2’s role in natural estrogen replacement is therefore a practical application and 
other studies have shown benefits in treating CaP using E2 therapy (Strax, 2005). It could 
therefore be implied that if a nutritional standard for E2 is established similar to those for 
other nutritional supplements then this could be advised especially for males after 50 
years old. In relation to the etiological model proposed by Giovannucci, (1999), there are 
points within that model where supplementation could be administered. Although 
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phytonutrients are seen as potential supplementation prior to PSA increase and the 
development of PINs which are important in the diagnosis of CaP, such intervention 
might act as a suitable prevention modality.   
Implications for Social Change 
The results appear to support the evidence that factors associated with CaP 
outcome such as PSA and E2 levels are influenced by isoflavone intervention that might 
provide an effective chemoprevention approach. The approach to determine the 
appropriate stage for chemoprevention is therefore the practical social change implication 
to which these findings should be focused. This study determined that participants 
undergoing SDP chemoprevention are ten times more likely to have higher levels of 
serum E2 than the control group. Therefore, social implications for a nutritional standard 
for E2 can be established similar to those for other nutritional supplements, especially for 
males 50 years and older. The study also has relevance to members of different ethnic 
groups who have higher incidence of CaP. Finally, the incidence of CaP continues to be 
greater in later age decades and the growing aging of the population and increased life 
expectancy require acceptable alternative prevention methods of prostate abnormalities. 
Conclusion 
The purpose of this meta-analysis was to determine the cumulative ES of eight 
randomized clinical trials where the experimental group received SDP as secondary 
prevention of CaP. From a clinical standpoint, the intervention is successful if the PSA 
levels are improved. While there has been valuable information gathered from this study, 
the need for additional research is warranted to conclusively determine SDPs role in 
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reducing PSA levels. Larger sample size of experimental groups as well as other factors 
such as duration and concentration of SDPs can be further explored. The results seem to 
acknowledge the benefits of E2 in cancer prevention and thus more rigorous exploration 
is recommended. The value as an SDP oral supplement or in hormonal replacement 
therapy for CaP and other cancers is worth pursuing. Studies that seek to understand the 
dynamics of a balance between PSA and E2 might also be invaluable to understanding 
therapeutic and chemo-preventive properties.  
More importantly, the results obtained from this analysis indicate the potential 
benefit of SDPs in the primary prevention of CaP. A new model to illustrate the role of 
the implementation of earlier intervention was designed. The proposed model was 
developed as The Dual Prevention Intervention Model, consisting of a dual prevention 
strategy. The access to intervention in this new model is conceptualized to provide 
options for SDP chemoprevention. Chemoprevention appears to occur through two 
defined strategies. First, the critical point at which primary prevention can be targeted 
through SDP to prevent any cellular damage to prostate tissue, and second, identification 
of the critical point at which secondary prevention can be targeted. In the present study, 
RCTs aimed at using SDPs as chemoprevention of further prostate disease or prevention 
of recurrent disease were assessed. The literature to date had not examined the role of 
SDP as primary prevention nor as secondary prevention within a public health 
framework. Although the findings of the correlation between direct intervention with 
SDPs and serum PSA was not statistically significant, the findings indicate that 
addressing secondary prevention can result in a change in serum PSA level towards the 
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desirec clinical direction of a lowered level. Secondly, serum SDP appears to have a 
direct influence on serum E2 levels which appear to be valuable for CaP outcome. The 
approach using this model is to provide optimum chemoprevention with the potential for 
improved health outcomes. The correlation between dietary and serum SDPs and 
subsequently the effect on both sPSA and sE2 for cancer chemoprevention appears to be 
supported by ES results. Moderator variables including intervention duration, quantity 
and concentration of experimental variables, and age did not show any significant effect 
on ES data. The test for heterogeneity was determined at 95% CI.  
The data inidcated that the level of sE2 maintained following SDP intervention, 
supports SDPs as valuable for estrogen replacement therapy. Estrogen replacement is 
presently a valuable therapeutic straegy for CaP treatment. As a natural alternative source 
it could be effective in reducing present incidence of CaP especially in poorer 
communities. Many underserved communities do not have access to medical care 
because of the lower socioeconomic status. Acess to early screening, preventive public 
health methods and subsequent medical intervention is lacking and results in greater 
disease burden and poorer health outcomes, especially among African Americans who 
suffer from the greates incidence and mortality from CaP.  
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Appendix A: Manual and Study Inclusion Form 
Intervention Characteristics of Study: Selected studies should be RCT designed. Study 
should specifically show intervention from use of the phytoestrogens (isoflavones) 
genistein and daidzein among the components. Response of PSA and Estradiol in 
treatment or placebo should be the primary main dependent variables been studied. They 
are the important variables for the intervention strategy and are the primary measured 
variables. Their association relating to effect size or magnitude and direction of treatment 
effect and CaP chemoprevention is important.  
Research Subjects: The RCTs should include subjects that are over 50 years old. 
However as indicated prior one study had an age range between 49.8 and 85.4 years old.  
Valuable study variables: These should include the independent variable isoflavones 
(genistein and daidzein) and dependent variables PSA and estradiol.  
Research methods: Studies needed to have both treatment and placebo groups. Baseline, 
pre-study, post-study information throughout the study was important. However, any lack 
of information on after study completion regarding follow-up would not deter selection. 
The treatment group should be matched by a placebo or control group that remain absent 
of any similarity to the employed treatment strategy.  
Cultural and Language Concerns: Studies should be published in an English scientific 
peer-reviewed journal. Publications can be from any country where such research was 
conducted.  
Publication Type: Primarily peer-reviewed RCTs 
Publication time frame: Published within the past 15 years.  
Coding Form  
Study ID: Publication Type – Published scientific journal articles 
Study Description: Randomized-controlled trials (RCTs) 
Study Setting: Studies were conducted in several settings including medical and radiation 
oncology clinics; Urology clinics, Minnesota Veterans Administration medical Center; 
local urologists; Gastroenterology clinics; Los Angeles surgical patients; Local hospitals; 
University of Massachusetts Teaching Hospital; University of California, Davis; Moffitt 
Community Clinical Oncology program, Florida. 
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Age Range of Participants: 
Mean Age of Participants: 
Standard Deviation:  
Target Population: 
i) universal  
ii) selective  
iii) inclusive  
 
Total confidence of target population: very weak; weak, moderate, strong, very strong 
Total sample size (beginning of study (BS)): 
Treatment group at BS: 
Control group at BS: 
Events: Reported study events 
Adverse events (AEs):    
Intervention Type:  
i) effect identification;  
ii) magnitude of effect;  
iii) direction of effect 
 
Intervention strategy Assurance/Confidence: 
i) very low confidence;  
ii) low confidence;  
iii) moderate confidence;  
iv) high confidence; and  
v) very high confidence 
 
Did information associating Phytoestrogens (Daidzein & Genistein) with PSA and 
estradiol responses identified in the studies? 
1) Yes – in all studies 
2) No – in most studies; in a few studies 
3) Some exclusions  
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Nature of the control groups: 
a) No treatment 
b) Mixed 
c) Placebo 
d) Other (specify) 
a. time-delayed;  
b. volume-delayed;  
c. concentration-delayed 
 
Duration of Intervention: (days; weeks; months; and years)  
 
a) Single session (specify) 
b) Multiple sessions (specify)  
c) Continuous sessions (specify if applicable)   
 
Length of treatment: 
Length of control: 
Length of follow-up: 
Total length of study and follow-up (if applicable):  
Periods of assessment: 
Pre-test, post-test 
Post-test only 
Pre-test, post-test, follow-up 
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Appendix B: Effect Size Criteria Description 
 
Intervention Criteria Assigned # 
for Criteria 
Description of Criteria 
 
Intervention characteristics 
 
1 
 
Both daidzein and genistein used in intervention 
 
 2 Only one isoflavone used in intervention 
 
 3 None used 
 
 4 Different isoflavones 
 
Respondents to Research 5 Diagnosed with CaP or HRC 
 
 6 Undergoing therapy or scheduled for surgery/therapies 
with increasing PSA 
  
 7 Completed therapy/active surveillance with increasing 
PSA 
 
Primary Variables 8 PSA levels 
 
 9 Estradiol levels 
 
 10 Available data for computing Effect Size data 
 
Research Methodology 11 Meets the requirements for designing and conducting 
RCTs including randomization and blinding process 
 
 12 Experimental groupings including Treatment and 
placebo/control subjects 
  
 13 Presently available statistics employed in data analysis 
  
Language/Cultural 
Requirements 
14 Unpublished or published in English 
 
 
Published or unpublished 
Time Frame 
15 ≤ 15 years ie. 1999 and later publications or unpublished 
work 
 
Publication Type 16 Publication in peer-reviewed scientific journal  
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Appendix C: Effect Size and Study Coding Form 
 
Study Level Coding  
 
Level of effect size coding 
1. Study ID 
2. Effect size variables 
Duration of phytoestrogen therapy 
Concentration of components 
 
3. Type of effect size 
a. 2 groups -- contrast in groups 
b. 3 or more groups -- contrast among groups  
4. Effect size data page 
5. Data providing Effect size:  
a. Means and SD  
b. t-value  
c. Correlation  
d. Hedges g  
e. Others 
6. Contrast in group designs:  
7. Sample size (N) 
8. Pre-Intervention Means 
9. Post-Intervention Means   
10. SDs 
11. Pooled Variance 
12. ES uncorrected 
13. Values of Effect Sizes  
14. Corrected SMD  
15. Standard Error of Means 
16. Inverse variance (weight) 
 
Characteristics and descriptive feature of study 
1. Bibliography 
2. Study  
3. Format published a) journal; b) unpublished  
4. Country published 
5. Year published 
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Features of publication methodology 
1. Study Design 
a. Experimental;  
b. Quasi-experiment;  
c. Cross-over 
2. Control group  
a. Similar intervention;  
b. Placebo;  
c. Other treatment;  
d. No treatment  
 
6. Study Design 
a. Experiment;  
b. Quasi-experiment  
c. Cross-over  
d. RCT 
7. Diagnostic and assessment instruments for CaP diagnosis 
8. Blinding of Researcher  
a. Yes;  
b. Nno;  
c. Partial, and  
d. Not reported 
 
Subject Assignment in study 
a) Random 
b) Non-random (explain) 
c) Other i.e. Cross-over (explain) 
 
Defining CaP inclusion threshold: 
a) Yes: indicate methods 
b) No: indicate methods  
 
Timelines for Data collection 
a) Baseline/pre-treatment 
b) During treatment 
c) Post-treatment 
d) Follow-up 
 
Role of experimenter during treatment 
a) Provides treatment 
b) Non-contact with subjects 
c) Directed treatment  
d) Uncertain i.e. not reported 
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Appendix D: Permission to Use REM Figure 
 
 
Subject : 
Re: re. Use of Random Effects Model 
figure 
Date : Tue, May 21, 2013 09:02 AM CDT 
From : Michael Borenstein <MichaelB@Meta-Analysis.com>  
To : Ruel Michelin <ruel.michelin@waldenu.edu>  
Thank you for your note. 
 
You are welcome to use any results achieved from our software,  
however, please be sure to cite our program as follows: 
Comprehensive Meta Analysis Version 2 
Borenstein, M., Hedges, L., Higgins, J., & Rothstein, H. 
Biostat, Englewood, NJ 2005 
 
Thank you again. 
 
Vivian Vargas 
Assistant Administrator 
 
 
 
At 07:42 PM 5/20/2013, you wrote: 
>Dear Dr. Borenstein, 
>                                 Good day. I would be extremely  
> appreciative if you could provide an email or attached word  
> document response giving permission to use a copy of your random  
> effects model figure in the dissertation research document been  
> prepared for ProQuest submission. Your quick response will be  
> highly appreciated. 
> 
>Respectfully, 
>Ruel Michelin. 
> 
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Curriculum Vitae 
 
Ruel Slyfield Michelin 
 
Summary of Qualifications and Experience 
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published data for future presentation/publication and for requesting of research 
grants  
 
Education  
 
2013 PhD, Public Health, Walden University, Minneapolis MN 
  
148 
2011 MPH (Honors), Environmental Health, American Public University, Charles Town, 
WV 
2009 Pre-Clinical Medical Studies, IUHS, St. Kitts, West Indies  
2006 Diploma, Clinical Tropical Medicine and Parasitology, West Virginia University, 
School of Medicine, Morgantown, WV 
2004 Graduate Certificate, Biotechnology and Microarray, FAES at NIH, Bethesda, MD 
2000 BS, Liberal Studies, Excelsior College, Albany, NY 
1992 Associate Diploma, Horticulture, University of Guelph, Ontario, Canada 
 
Professional Memberships 
 
2002 – Present Member, Assoc. of Southeastern Biologists (ASB) 
2003 – Present Member, American Society of Microbiology (ASM) 
2004 – Present Canadian Association of Clinical Microbiology and Infectious Diseases 
(CACMID)  
2007 – Present Member, American Public Health Association (APHA) 
2007 – Present Member, European Association of Cancer Research (EACR) 
2010 – Present Member, Doctors for America, (DFA)  
 
Selected Abstracts  
 
1. Michelin, R., Johnson, C., Leitner, W., Whittaker, J., & Gutierrez, M. Survivability and 
the opportunity for disease transmission: Observations of the Ixodes pacificus. Book of 
Abstracts. 2012 American Society of Tropical Medicine & Hygiene conference, 
November 11 – 15, 2012, Atlanta, Georgia. 
 
2. Michelin, R., Johnson, C., Leitner, W., Whittaker, J., & Gutierrez, M. Effect of 
phytoestrogen intake duration on PSA level and prostate cancer recurrence: A meta-
analysis of randomized studies. Book of Abstracts. 2012 World Cancer Congress, August 
27-30, 2012, Montréal, Canada.  
 
3. Michelin, R., Johnson, C., Leitner, W., Frederick, L., Shureiqi, I., Whittaker, J., & 
Gutierrez, M. Effects of climate change on Aspergillus species and consequences for 
agriculture and human health: A meta-analysis. Southeastern Biology, 59(2), 154. ASB 
73
rd
 Annual Meeting, April 4-7, 2012, The University of Athens, GA.  
 
4. Michelin R, Frederick L, Benjamin E, Adelore T and Williams A. Purification and 
Partial-Characterization of an Antifungal Metabolite from an Axenic Culture of an 
Unidentified Species of Bacillus. Book of Abstracts. IFBLS 26
th
 World Congress, 
Stockholm, Sweden. June 13-18, 2004. 
 
5. Michelin R, Lobban K, Jenkins M, Adelore T, Frederick L and Williams A. Comparative 
in vitro Analysis of Novel Antifungal Compound using Etest and Disk Diffusion Assay. 
Book of Abstracts: Canadian Assoc of Clinical Microbiol and Infect Diseases 7
th
 Conf. 
Regina, Nova Scotia, Canada. March 12-16, 2004. 
 
6. Michelin R, Frederick L, Oladeinde F, Kinyua A and Williams A.  Isolation and 
Purification Does Not Affect Cytotoxic Ability of Protein Fraction. ISPPP 2005, 25
th
 
  
149 
International Symposium & Exhibit on the Separation of Proteins, Peptides & 
Polynucleotides, November 6 – 9, 2005, St. Pete Beach, Florida, USA. 
 
7. Michelin R, Frederick L, Kinyua A, Stewart J, Oladeinde F and Williams A. Nematicidal 
Activity of Compounds from New Strain of Bacillus mojavensis. The American Society 
of Tropical Medicine and Hygiene (ASTMH), 54
th
 Annual Meeting, December 11 – 15, 
2005, Hilton Washington Hotel & Towers, Washington, DC, USA.  
 
8. Michelin R, Frederick L, Adelore T, Benjamin E, Jenkins M and Williams A. 
Identification, Purification and in vitro Analysis of an Antifungal Metabolite from an 
Unidentified Bacillus species. 72
nd
 Conjoint Meeting on Infectious Diseases. Canadian 
Association for Clinical Microbiology and Infectious Diseases, November 7-10, 2004, 
Delta Regina Hotel, Regina, Saskatchewan.  
 
9. Michelin R, Frederick L, Batta E, Benjamin E and Williams A. Comparative in vitro 
Assays Using Novel Antibacterial Compound against Clostridium perfringens. Book of 
Abstracts, ASM BioDefense Research Meeting. Baltimore Marriot Waterfront, March 7-
10, 2004, Baltimore, Maryland. 
 
10. Oladeinde F, Kinyua A, Laditan A, Michelin R, Makinde M, Williams A, Kennedy A, 
Taylor E and Bronner Y. Effect of Cnidoscolus aconitifolius (Euphorbiaceae) on blood 
glucose levels in Alloxan-induced Diabetic mice. Abstr. 4
th
 Annual Levine Symposium: 
Advances in Diabetics Research, Nov. 4-8, 2003, Universal City, California.  
 
11. Arzu-Thompson, K., Austin, L., Michelin, R., & Frederick, L. (2007). Observations on 
the effect of culture filtrate of a strain of Bacillus mojavensis on germination of spores of 
Alternaria and Ulocladium. Southeastern Biology, 54(2), 136.  
 
12. Knight, C., Austin, L., Michelin, R., & Frederick, L. (2007). The induction of a dark 
strain of Bacillus mojavensis as an endophyte in corn and cotton plants. Southeastern 
Biology, 54(2), 136.  
 
Selected Publications 
 
Oladeinde, F., Kinyua, A., Laditan, A., Michelin, R., Makinde, M., Williams, A., et al. (2003). 
Phytochemical and anti-diabetic studies of Cnidoscolus aconitifolius (Euphorbiaceae), 
West Indian Medical Journal, 53 (Suppl 1): 30. 
Oladeinde, F., Kinyua, A., Laditan, A., Michelin, R., Bryant, J., Denaro, F., et al. (2007). Effect 
of Cnidoscoluis aconitifolius leaf extract on blood glucose and insulin levels of inbred 
type 2 diabetic mice. Cellular and Molecular Biology, 53(3), 34-41. 
Johnson, C., Oladeinde, F., Kinyua, A., Michelin, R., Makinde, J., Jaiyesimi, A., et al. (2008). 
Comparative assessment of total phenolic content in selected medicinal plants. Nigerian 
Journal of Natural Products and Medicine, 12, 40-42. 
  
150 
Johnson, C., Long-ze, L., Harnly, J., Oladeinde, F., Kinyua, A., Michelin, R., & Bronner, Y. 
(2011). Identification of the Phenolic Components of Vernonia amygdalina and Russelia 
equisetiformis, Journal of Natural Products, 4, 57-64.  
 
Work Experience 
 
2012–Present Executive Director, Cariam Health Consulting, LLC, Rockville MD 
2003–2008 Research Assistant, Dept. of Biology, Morgan State University, Baltimore, MD 
2001–2003 Graduate Research, Dept. of Biology, Howard University, Washington, DC 
1998--1999 Surgical Technician, BMT Unit, University of Michigan Hospitals, Ann Arbor, 
MI 
1997–1998 Medical Assistant, University of Michigan Hospitals, Comprehensive Cancer 
Clinic, Ann Arbor, MI 
 
